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Abstract
Hypertension is a significant public health problem worldwide and is a major
modifiable risk factor for cardiovascular disease. The dynamics of guidelinesrecommended blood pressure (BP) control and adherence to antihypertensive
medications in incident hypertensives remain unclear. This dissertation aims to assess
guidelines-recommended

BP

management,

adherence

to

antihypertensive

medications, and factors associated with poor BP control among newly diagnosed
hypertensive patients in the UAE. A retrospective chart review of 5308 newly treated
hypertensives across emirate of Abu Dhabi, UAE, in 2017 was conducted. These
patients were diagnosed by the treating physician according to ambulatory (ABPM),
or home-based BP monitoring (HBPM) were considered. After collecting data
regarding basic details and BP measurements, patients were followed up for six
months. Changes in the BP, adherence to antihypertensive treatment within the first
six months of treatment initiation, and factors associated with achieving target BP and
medication adherence were assessed. Patients who did not reach BP targets despite
taking three or more antihypertensive medications were defined as treatment-resistant
hypertension (TRH). The mean BP was 133.9 ± 72.9 mmHg at baseline and 132.7 ±
72.5 mmHg at six months. Among the sample, only 31.7% of the patients aged ≤40
years, 37.5% with a body-mass index (BMI) of ≥ 25 kg/m2, 45.4% smokers, and
37.5% patients with diabetes reached the BP target (<130/80 mmHg). Patients with
lower BMI and those treated in secondary care settings were more likely to achieve
BP targets. The overall adherence to antihypertensive treatment was 42%. Male
gender, secondary care settings, and diabetes were associated with adherence. Among
189 patients using three or more antihypertensive medications, only 34% (n =64) were
adherent to the treatment, and only 13.7% (n =26) reached the BP target. The
prevalence of TRH was 20.1%. To the best of our knowledge, this is the first work in
the UAE to investigate longitudinal BP control and medication adherence in a large
community cohort of patients with incident hypertension. The findings provide
contemporary evidence on guidelines-recommended BP management and adherence
to treatment among newly treated hypertensive patients. BP control and adherence to
antihypertensive therapy were suboptimal in the UAE. Moreover, TRH in this
population is relatively very high and requires urgent public health attention.

viii
Keywords: Blood pressure, control, cardiovascular, guidelines, goals, hypertension,
medication adherence, treatment-resistant hypertension, United Arab Emirates.
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ھﺬه اﻟﺮﺳﺎﻟﺔ إﻟﻰ ﺗﻘﯿﯿﻢ اﻹدارة اﻟﺴﺮﯾﺮﯾﺔ ﻟﻀﻐﻂ اﻟﺪم ،واﻻﻟﺘﺰام ﺑﺎﻷدوﯾﺔ اﻟﺨﺎﻓﻀﺔ ﻟﻠﻀﻐﻂ ،واﻟﻌﻮاﻣﻞ اﻟﻤﺮﺗﺒﻄﺔ
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اﻟﻤﺘﺤﺪة .ﺗﻤﺖ ﻣﺮاﺟﻌﺔ اﻟﺮﺳﻢ اﻟﺒﯿﺎﻧﻲ ﺑﺄﺛﺮ رﺟﻌﻲ ﻟـ  5308ﻣﺮﯾﺾ ﻣﻦ ﻣﺮﺿﻰ ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم اﻟﺬﯾﻦ ﻋﻮﻟﺠﻮا
ﺣﺪﯾﺜًﺎ ﻓﻲ ﺟﻤﯿﻊ أﻧﺤﺎء إﻣﺎرة أﺑﻮ ظﺒﻲ ،اﻹﻣﺎرات اﻟﻌﺮﺑﯿﺔ اﻟﻤﺘﺤﺪة ،ﻓﻲ ﻋﺎم  .2017ﺑﻌﺪ ﺟﻤﻊ اﻟﺒﯿﺎﻧﺎت اﻟﻤﺘﻌﻠﻘﺔ
ﺑﺎﻟﺘﻔﺎﺻﯿﻞ اﻷﺳﺎﺳﯿﺔ وﻗﯿﺎﺳﺎت ﺿﻐﻂ اﻟﺪم ،ﺗﻤﺖ ﻣﺘﺎﺑﻌﺔ اﻟﻤﺮﺿﻰ ﻟﻤﺪة ﺳﺘﺔ أﺷﮭﺮ .ﺗﻢ ﺗﻘﯿﯿﻢ اﻟﺘﻐﯿﯿﺮات ﻓﻲ ﺿﻐﻂ اﻟﺪم،
وﻣﺪى اﻻﻟﺘﺰام ﺑﺎﻟﻌﻼج اﻟﺨﺎﻓﺾ ﻟﻠﻀﻐﻂ ﺧﻼل اﻷﺷﮭﺮ اﻟﺴﺘﺔ اﻷوﻟﻰ ﻣﻦ ﺑﺪء اﻟﻌﻼج ،واﻟﻌﻮاﻣﻞ اﻟﻤﺮﺗﺒﻄﺔ ﺑﺘﺤﻘﯿﻖ
ﺿﻐﻂ اﻟﺪم اﻟﻤﺴﺘﮭﺪف .ﺗﻢ ﺗﻌﺮﯾﻒ اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﻟﻢ ﯾﺼﻠﻮا إﻟﻰ ﺿﻐﻂ اﻟﺪم اﻟﻤﺴﺘﮭﺪف ﻋﻠﻰ اﻟﺮﻏﻢ ﻣﻦ ﺗﻨﺎول ﺛﻼﺛﺔ
أو أﻛﺜﺮ ﻣﻦ اﻷدوﯾﺔ اﻟﺨﺎﻓﻀﺔ ﻟﻠﻀﻐﻂ ﻋﻠﻰ أﻧﮭﻢ ذوي ﺿﻐﻂ اﻟﺪم اﻟﻤﺮﺗﻔﻊ اﻟﻤﻘﺎوم ﻟﻠﻌﻼج .ﻛﺎن ﻣﺘﻮﺳﻂ ﺿﻐﻂ اﻟﺪم
ھﻮ72.9±133.9 :ﻣﻢ زﺋﺒﻖ ﻓﻲ ﺑﺪاﯾﺔ اﻟﺪراﺳﺔ و  72.5 ± 132.7ﻣﻢ زﺋﺒﻖ ﺑﻌﺪ ﺳﺘﺔ أﺷﮭﺮ .وﺻﻞ  ٪31.7ﻓﻘﻂ
ﻣﻦ اﻟﻤﺮﺿﻰ اﻟﻤﺴﺘﮭﺪﻓﯿﻦ اﻟﺬﯾﻦ ﺗﻘﻞ أﻋﻤﺎرھﻢ ﻋﻦ  40ﻋﺎ ًﻣﺎ ،و) (٪37.5ﻣﺆﺷﺮ ﻛﺘﻠﺔ ﺟﺴﻤﮭﻢ  25ﻛﺠﻢ /م2
و) (٪45.4ﻣﻦ اﻟﻤﺪﺧﻨﯿﻦ و) (٪37.5ﻣﻦ ﻣﺮﺿﻰ اﻟﺴﻜﺮي إﻟﻰ ﺿﻐﻂ اﻟﺪم اﻟﻤﺴﺘﮭﺪف )>  80/130ﻣﻢ زﺋﺒﻖ(.
وﻛﺎن ﻣﻦ اﻷرﺟﺢ أن ﯾﺤﻘﻖ اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﻌﺎﻧﻮن ﻣﻦ اﻧﺨﻔﺎض ﻣﺆﺷﺮ ﻛﺘﻠﺔ اﻟﺠﺴﻢ واﻟﺬﯾﻦ ﻋﻮﻟﺠﻮا ﻓﻲ أﻣﺎﻛﻦ
اﻟﺮﻋﺎﯾﺔ اﻟﺜﺎﻧﻮﯾﺔ ﺿﻐﻂ اﻟﺪم اﻟﻤﺴﺘﮭﺪف .ﻛﺎن ﻣﻌﺪل اﻻﻟﺘﺰام اﻟﻌﺎم ﺑﺎﻟﻌﻼج اﻟﺨﺎﻓﺾ ﻟﻠﻀﻐﻂ ھﻮ  .٪42ﯾﺮﺗﺒﻂ ﺑﺠﻨﺲ
اﻟﺬﻛﻮر ،وإﻋﺪادات اﻟﺮﻋﺎﯾﺔ اﻟﺜﺎﻧﻮﯾﺔ ،وﻣﺮض اﻟﺴﻜﺮي ﺑﺎﻻﻟﺘﺰام .ﻣﻦ ﺑﯿﻦ  189ﻣﺮﯾﻀًﺎ ﯾﺴﺘﺨﺪﻣﻮن ﺛﻼﺛﺔ أو أﻛﺜﺮ
ﻣﻦ اﻷدوﯾﺔ اﻟﺨﺎﻓﻀﺔ ﻟﻠﻀﻐﻂ ،ﻛﺎن  ٪34ﻣﻨﮭﻢ ﻓﻘﻂ )ﻋﺪد =  (64ﻣﻠﺘﺰ ًﻣﺎ ﺑﺎﻟﻌﻼج ،ووﺻﻞ  ٪13.7ﻣﻨﮭﻢ ﻓﻘﻂ )ﻋﺪد
=  (26إﻟﻰ ﺿﻐﻂ اﻟﺪم اﻟﻤﺴﺘﮭﺪف .ﻛﺎن ﻣﻌﺪل اﻧﺘﺸﺎر ﺿﻐﻂ اﻟﺪم اﻟﻤﺮﺗﻔﻊ اﻟﻤﻘﺎوم ﻟﻠﻌﻼج ﻓﻲ اﻟﻤﺮﺿﻰ ھﻮ .٪20.1
اﻟﻤﺴﺎھﻤﺎت اﻟﻜﺒﯿﺮة :ﻋﻠﻰ ﺣﺪ ﻋﻠﻤﻨﺎ ھﺬا ھﻮ اﻟﻌﻤﻞ اﻻﺳﺘﻘﺼﺎﺋﻲ اﻷول ﻓﻲ دوﻟﺔ اﻹﻣﺎرات اﻟﻌﺮﺑﯿﺔ اﻟﻤﺘﺤﺪة ﻟﻼﺳﺘﻘﺼﺎء
ﻓﻲ ﻣﺪى اﻟﺴﯿﻄﺮة ﻋﻠﻰ ﺿﻐﻂ اﻟﺪم واﻻﻟﺘﺰام ﺑﺎﻷدوﯾﺔ ﻓﻲ ﻣﺠﻤﻮﻋﺔ ﻛﺒﯿﺮة ﻣﻦ اﻟﻤﺮﺿﻰ اﻟﻤﺼﺎﺑﯿﻦ ﺑﺎرﺗﻔﺎع ﺿﻐﻂ
اﻟﺪم اﻟﺤﺪﯾﺚ .ﺗﻘﺪم اﻟﻨﺘﺎﺋﺞ أدﻟﺔ ﻣﻌﺎﺻﺮة ﻋﻠﻰ اﻹدارة اﻟﺴﺮﯾﺮﯾﺔ ﻟﻀﻐﻂ اﻟﺪم واﻻﻟﺘﺰام ﺑﺎﻟﻌﻼج ﺑﯿﻦ ﻣﺮﺿﻰ ارﺗﻔﺎع
ﺿﻐﻂ اﻟﺪم اﻟﻤﻌﺎﻟﺠﯿﻦ ﺣﺪﯾﺜًﺎ .ﺗﺒﯿﻦ أن اﻟﺘﺤﻜﻢ ﻓﻲ ﺿﻐﻂ اﻟﺪم واﻻﻟﺘﺰام ﺑﺎﻟﻌﻼج اﻟﺨﺎﻓﺾ ﻟﻠﻀﻐﻂ دون اﻟﻤﺴﺘﻮى اﻷﻣﺜﻞ
ﻓﻲ اﻹﻣﺎرات اﻟﻌﺮﺑﯿﺔ اﻟﻤﺘﺤﺪة .ﻋﻼوة ﻋﻠﻰ ذﻟﻚ ﻓﺈن ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم اﻟﻤﻘﺎوم ﻟﻠﻌﻼج ﻓﻲ ھﺬه اﻟﻔﺌﺔ ﻣﻦ اﻟﺴﻜﺎن
ﻣﺮﺗﻔﻊ ﻧﺴﺒﯿًﺎ وﯾﺘﻄﻠﺐ اھﺘﻤﺎ ًﻣﺎ ﻋﺎﺟﻼً ﻣﻦ اﻟﺼﺤﺔ اﻟﻌﺎﻣﺔ.
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Chapter 1: Introduction
1.1 Overview of hypertension
Hypertension or high blood pressure (BP) is defined as persistent BP of greater
than or equal to 140/90 mmHg during the resting stage of the heart. In 2003, the
Seventh Report of Joint National Committee (JNC7) defined hypertension as a chronic
elevation of resting systolic blood pressure (SBP) above the threshold value of 120/80
mmHg and/or receiving therapy for the indication of BP lowering (1). Maintaining
optimal BP is of crucial importance for the perfusion of vital organs, such as the brain,
heart, and kidneys. Delivering oxygen through blood flow is of greater immediate
importance for adequate functioning of these vital organs. BP reacts to changes in the
physiological environment in the body to maintain organ perfusion in a wide variety
of ways via the sympathetic nervous system, renin–angiotensin–aldosterone system,
and alteration of plasma volume. In 1896, first Riva-Rocci and then Korotkoff
developed the cuff sphygmomanometer for measuring BP (2,3).
Hypertension is a disorder of circulatory regulation, and the etiology of
hypertension was first described by Page et al. in 1949 (4). BP regulation entails a
series of complex interactions with the kidney, vascular endothelium, the central
nervous system, peripheral nervous system, and adrenal and pituitary glands. Various
pathophysiological factors could lead to hypertension, and the etiological mechanism
of each of these is depicted in Figure 1 (extracted from Carretero et al. (5)).
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Figure 1: Pathophysiological mechanism of hypertension. AME – apparent
mineralocorticoid excess; GRA – glucocorticoid-remediable aldosteronism; CNS –
central nervous system.

In 2003, Oparil et al. (6) described the potential pathophysiological causes of
hypertension, and they can be summarized as:
1. Long-term high sodium intake, perhaps coupled with inadequate dietary intake of
potassium and calcium.
2. Overproduction of sodium-retaining hormones and vasoconstrictors.
3. Deficiencies of vasodilators, such as prostacyclin, nitric oxide, the natriuretic
peptides, and/or a variety of other vasodilator peptides (e.g., the angiotensin
peptide, calcitonin gene-related peptide, substance P, and/or adrenomedullin).
4. Alterations in adrenergic receptors that influence heart rate, inotropic properties of
the heart, vascular tone and altered cellular ion transport.
5. Increased sympathetic nervous system activity, perhaps from heightened exposure
or response to psychosocial stress.
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6. Increased or inappropriate renin secretion with resultant increased production of
angiotensin II and aldosterone.
7. Alterations in expression of the kallikrein–kinin system.
8. Diabetes mellitus, insulin resistance, being obese or overweight, and increased
activity of related vascular growth factors.
9. Abnormalities of resistance vessels, including selective lesions in the renal
microvasculature.
Although several factors contribute to the pathogenesis and maintenance of BP
elevation, renal mechanisms play a vital role in renal salt absorption and water
retention. Several interacting pathways such as an increase in natriuretic peptides,
vascular remodeling, and sympathetic nervous system activity play major roles in
increasing BP and mediating target organ damage.
1.1.1 Screening and diagnosis of hypertension
1.1.1.1 Screening
The auscultatory BP measurements by means of sphygmomanometer described
by Riva-Rocci is used for oscillometric BP measurement and is the standard
measurement

method

for

detecting

peripheral

BP.

A

well-calibrated

sphygmomanometer should be used to measure BP and is routinely used in patient
screening, manual sphygmomanometer is more accurate than the automated electronic
measurement. The electronic devices are also used for self-measurement for home
screening and follow up. BP is calculated from the mean of the systolic and diastolic
jerks.
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Each individual from the age of three years or above is recommended to have
their BP monitored by a healthcare professional at least once a year (7–9). Screening
asymptomatic adults for hypertension can benefit in early detection and delayed
progression of the disease. In 2007, The United States Preventive Services Task Force
(USPSTF) established guidelines for the screening of high BP in adults (7) and
reaffirmed the recommendations in 2015 (8). The USPSTF recommendations are
summarized in Table 1.
Table 1: Screening of high BP in adults
Population
Recommendation
Risk assessment

Screening tests

Screening interval

Adults aged ≥ 18 years without known hypertension.
Screening for high BP: To obtain BP measurements outside
the clinical setting for diagnostic confirmation.
Individuals at increased risk for high BP are those who have
high-normal BP (130–139/85–89 mmHg), those who are
overweight or obese, and the African–American population.
Office measurement of BP is usually done with a manual or
automated sphygmomanometer.
The mean of two BP measurements to be taken while the
patient is seated by allowing five minutes or more between
entry into the office and BP measurement, using an
appropriately sized arm cuff and by placing the patient’s
arm at the level of his or her right atrium. Furthermore,
multiple measurements over time are shown to have a better
positive predictive value than a single measurement.
Ambulatory and home BP monitoring should be used to
confirm a diagnosis of hypertension after initial screening.
Adults aged ≥ 40 years or above and individuals at increased
risk for high BP should be screened annually.
Adults aged 18 to 39 years with normal BP (lower than
130/85 mmHg) who do not have other risk factors should
be rescreened every three to five years.
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1.1.1.2 Diagnosis
Casual BP measurements can barely estimate the daily vascular load.
Measurement of BP is an exclusive method that can confirm the diagnosis of
hypertension. Correct measurement of BP and interpretation of results are essential in
the diagnosis of hypertension. It is important to note that measuring BP at two to three
cycles is not sufficient to confirm the diagnosis. White-coat hypertension (BP readings
that are consistently elevated in the doctor’s office or clinic) and masked hypertension
(BP readings that are consistently elevated in out-of-clinic environments but normal
in the clinic) are other types of hypertensions that lead to underdiagnosis of the patient
condition.
According to the evidence-based guidelines, there is a grading of hypertension
according to the BP levels (9–15). The summary of recently updated American,
European, United Kingdom (UK), and other international guidelines recommended BP
thresholds for the diagnosis and BP control according to age are presented in Table 2.
These guidelines recommend maintaining a BP of 120–130 and less than 80 mmHg in
all patients to prevent the complications associated with high BP.
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Table 2: Classification of hypertension and BP targets according to the international
guidelines
ACC/AHA
2017 (9)

ESC/ESH 2018
(11)

SBP <120
mmHg and
DBP < 80
mmHg
SBP 120–129
mmHg and
DBP < 80
mmHg

SBP 120–129
mmHg and/or
DBP 80–84
mmHg

Stage 1
hypertension

SBP 130–139
mmHg or
DBP 80–89
mmHg

SBP 140–159
mmHg and/or
DBP 90–99
mmHg

Stage 2
hypertension

SBP ≥ 140
mmHg or
DBP ≥ 90
mmHg

SBP 160–179
mmHg and/or
DBP 100-109
mmHg

Hypertension
crises

SBP > 180
and/or DBP
>120

SBP ≥180 mmHg
and/or DBP ≥110
mmHg

< 130/80
mmHg
< 140/80
mmHg
< 140/80
mmHg

130/80 mmHg
(18–65 years)
< 140/80 mmHg
(> 65 years)

Normal BP

Elevated BP

BP targets (age)
18–64
65–80
> 80

SBP 130–139
and/or DBP 85–89

-

NICE
guideline
2019 (10)

SBP <140
and/or DBP
< 90 mmHg

SBP 140–
159 mmHg
and/or DBP
90–99
mmHg
SBP 160–
179 mmHg
and/or DBP
100–120
mmHg
SBP ≥ 180
mmHg
and/or DBP
≥120 mmHg
< 140/90
mmHg
(18–80
years)
< 150/90
mmHg

ISH 2020 (15)
SBP <130 mmHg
and/or DBP < 85
mmHg
SBP 130–139 mmHg
and/or DBP 85–89
mmHg
SBP 140/159 mmHg
and/or DBP 90–99
mmHg
SBP ≥ 160 mmHg
and/or DBP ≥ 100
mmHg

-

< 130/80 mmHg
< 140/90 mmHg
-

SBP: systolic blood pressure; DBP: diastolic blood pressure; ACC/AHA: American College of
Cardiology/American Heart Association; ESC/ESH: European Society of Cardiology/European Society
of Hypertension; NICE: The National Institute for Health and Care Excellence; ISH: International
Society of Hypertension.

Current clinical guidelines from the United States of America (USA) (9,16),
UK (10), Europe (11), Canada (12), Australia (13), Japan (14), and the International
Society of Hypertension (ISH) (15) recommend using ambulatory BP monitoring
(ABPM) to confirm the diagnosis of hypertension in people with suspected
hypertension. These guidelines highlighted two class I recommendations: (a) The
diagnosis of hypertension should be based on repeated clinical BP measurements on
more than a single visit, except when hypertension is severe; (b) ABPM or home-based
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BP monitoring (HBPM) is recommended to confirm the diagnosis of hypertension, the
effects of hypertension treatment, and identify the possible cause of side-effects such
as symptomatic hypotension.
Because of the benefits of multiple measurements, absence of observer bias,
and lack of white-coat effect, ABPM is more accurate than in-clinic measurements and
HBPM in diagnosing hypertension (17). The utilization of ABPM is expected to
reduce unnecessary treatment in people who do not have true hypertension.
Furthermore, measurements obtained through ABPM and HBPM are lower by
approximately 5 to 10 mmHg than routine office measures. ABPM readings are lower
at night, and the physiologic nocturnal BP “dip” aggregates and compromises the local
vascular supply in some patients. This loss of dip is a dominant predictor of
cardiovascular disease (CVD) risk, particularly the risk of thrombotic stroke (18). It is
worth noting that the diagnosis of hypertension does not automatically entail drug
therapy for the patient; this decision depends on the clinician’s judgment.
1.1.2 Epidemiology of hypertension
1.1.2.1 Worldwide
Hypertension is a serious medical condition, and an estimated 1.3 billion
people worldwide have hypertension (19). It is one of the most prevalent causes of
premature death worldwide. The Framingham Heart Study in 1961 was one of the first
epidemiological studies to report the prevalence of hypertension and its consequences
in a longitudinal cohort (20).
One of the global targets concerning noncommunicable diseases is to decrease
the prevalence of hypertension by 25% by 2025 (21,22). The findings of the Global
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Burden of Disease (GBD) study, 2015, revealed that exposure to hypertension
accounted for 10.7 million deaths (33.2% of deaths attributed to all risk factors) and
contributed to nearly 212 million global disability-adjusted life years (DALYs) (23).
Furthermore, uncontrolled hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) has
increased substantially from 605 to 978 million from 1980 to 2010 (24). This has
resulted in high BP moving up from the fourth-ranked risk factor for burden of disease
in 1990 to the leading risk factor in 2010 (25). In a comparative risk assessment of 84
risk factors in 195 regions from 1999 to 2017, hypertension ranked at the topmost
position for global disease burden, accounting for 10.4 million (95% uncertainty
interval [UI]: 9.39–11.5 million) deaths and 218 million (95% UI: 198–237 million)
DALYs (26). Understanding the burden of global hypertension, the 2017 ACC/AHA
BP guidelines in adults have lowered the threshold for early diagnosis of hypertension
from 140/90 mmHg to 130/80 mmHg (9). In accordance with the revised guidelines,
it is estimated that the prevalence of hypertension for patients 20–44 years of age is
30% in men and 19% in women and for 65–74 years of age is 77% for men and 75%
for women (9).
1.1.2.2 Hypertension in the UAE
The first incidence of hypertension in the UAE among its citizens was reported
by Salahudeen et al. in 1987 (27) (prevalence data unavailable). The prevalence of
hypertension between 1989 and 1992 was reported by Musaiger et al. in 1994 (28).
The overall increased prevalence of hypertension was 20%, ranging from 14.3% in
1989 to 11.9% in 1992 and was higher in the UAE nationals (12.6%) than non-UAE
nationals (8.1%). Soon after, in 1995, el Mugamer et al. estimated the prevalence of
hypertension among Bedouin Emirati tribes in the UAE (29). In this study, the
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prevalence of hypertension among 322 participants was 19% (n = 61), and a quarter
(n = 80) had an SBP >140 mmHg. In 1998, the prevalence of hypertension was 23.9%
(29). Until this period, epidemiological evidence of hypertension in the UAE was
limited.
In 1998, the Ministry of Health (MoH) undertook the initiative to conduct the
first National Epidemiological Study to examine the extent of hypertension among
UAE citizens (NESH). A National Committee for Hypertension Screening, Detection,
Intervention, and Follow-up Program (NESH-UAE) was formed. The study was
conducted in different emirates (Sharjah, Abu Dhabi, and Al Ain), and the preliminary
findings were reported in 1999 (30). In the NESH-UAE study, hypertension was
defined as SBP >140 mmHg or DBP > 90 mmHg or reported treatment with one or
more antihypertensive medications for controlling BP. Of 3,150 participants surveyed,
hypertension among UAE nationals was 36.6% (95% confidence interval [CI]: 34.9 to
38.3). Higher prevalence was identified in females: 53%, 95% CI: 50.1 to 55.8 versus
47% males, 95% CI: 44.1 to 47; on treatment 41% (95% CI: 38.1 to 43.8), and only
19% (95% CI: 16.8 to 21.3) had their BP under control (30). An interesting finding of
this study was that a quarter of the participants (n = 289) fell within the younger
population (< 40 years age) (25%, 95% CI: 22.6 to 27.6).
A matched case-control survey investigating the relationship between
hypertension and lifestyle factors was conducted between 2001 and 2002 on 426
hypertensive adults aged 20–65 years in Al Ain city, UAE (31). Among hypertensive
patients, the mean SBP was found to be 141.9 ± 17.1 (SD: standard deviation), and
DBP was 92.7 ± 9.8 than controls (SBP 116.8 ± 8.7 and DBP 75.7 ± 6.2). Hypertension
was higher in men, aged 40–49 years, illiterates, and those with low income. This study
also identified a strong association between obesity, medium/higher income, history
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of diabetes, and low physical activity as significant risk factors for hypertension in the
UAE.
In the last two decades, several researchers have actively investigated the
epidemiology of high BP across different populations in the UAE. Most of these
studies are community-based, cross-sectional studies (32–38), investigating the
prevalence, awareness, and treatment (34,35), among youth (36,37), lifestyle
behaviors (39), underdiagnosis, and undertreatment of hypertension (40) and an
association between hypertension and other comorbidities (36,41). Since the initial
recognition of hypertension in the UAE, the epidemiology of high BP has been a
leading determinant of mortality and morbidity. The temporal trend of hypertension
prevalence according to the NCD Risk Factor Collaboration data (42) is presented in
Figure 2.
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Figure 2: Temporal trend of hypertension across various populations in the UAE
1.1.3 Complications of hypertension
High BP is strongly and directly related to vascular and overall mortality in
middle and old age. Higher BP affects structural and functional changes in the
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vasculature and heart. With each six-mmHg increase in DBP, the risk of morbidity and
mortality is doubled (43).
Better control of hypertension prevents morbidity and mortality. Each 10mmHg reduction in SBP is associated with a decreased risk of cerebrovascular disease
by approximately 35% (44). Cardiovascular complications are a major cause of
morbidity and mortality in primary hypertension. Left ventricular hypertrophy through
systolic or diastolic dysfunction is associated with heart failure, myocardial ischemia,
ventricular arrhythmias, and sudden death. It is also a major predisposing cause of
ischemic and hemorrhagic stroke. The incidence of subsequent cognitive decline,
dementia, and Alzheimer's disease are higher in hypertensive patients than nonhypertensive patients. Chronic hypertension causes injury in vascular, glomerular, and
tubulointerstitial compartments within the kidney and accounts for around 25% of endstage kidney disease. Complications associated with hypertension are encapsulated in
Table 3.
Table 3: Complications of hypertension in premature morbidity and mortality
End-organ
Brain

Heart

Kidney

Other emergencies

Complications
Thrombotic stroke
Ischemic stroke
Embolic stroke
Hemorrhagic stroke
Angina pectoris
Coronary artery disease
Congestive heart failure
Left ventricular diastolic dysfunction
Renal arterial disease
End-stage renal disease
Embolic renal disease
Diastolic renal disease
Aortic aneurysm
Malignant hypertension
Pheochromocytoma
Eclampsia in women
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Hypertension increases the risk of premature cardiovascular disease (CVD)
and often coexists with other risk factors, such as being obese or overweight, unhealthy
diet, and physical inactivity. A meta-analysis on hypertension of over one-million
adults across all age groups revealed that for every 20 mmHg increase in SBP and 10
mmHg increase in DBP, the risk of death from CVD or stroke doubles (45).
1.1.4 Risk factors for high blood pressure
Although the etiology of hypertension remains obscure, several risk factors are
strongly and independently associated with it. The onset of hypertension usually
occurs between 25 and 50 years of age. Factors that exacerbate this condition include
age, race, obesity, family history of hypertension, malnutrition, increased salt intake,
excess alcohol consumption, cigarette smoking, sleep apnea, unhealthy eating habits,
physical inactivity, polycythemia, excess use of nonsteroidal anti-inflammatory drugs
(NSAIDs), and low potassium intake. Some of the most crucial risk factors that lead
to an increased incidence of hypertension are discussed in Table 4.
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Table 4: Potential risk factors for hypertension
Age
Family history
Race
High sodium diet
Excess alcohol
consumption
Physical inactivity
Cigarette smoking

Obesity

Stress

NSAIDs

Advanced age is associated with increased SBP and an increased
incidence of hypertension.
Hypertension is two times more common in subjects with a family
history of hypertension.
Hypertension is more common, more severe, and occurs earlier among
black people and those of African descent.
Sodium intake > 3 g/day increases the risk of hypertension.
Excess alcohol intake is associated with the development of
hypertension.
Physical inactivity increases the risk of hypertension
Smoking raises BP by increasing plasma norepinephrine. The
synergetic effect of smoking and hypertension on cardiovascular risk
has been well documented
Obesity and excess weight are major risk factors for hypertension and
are determinants for high BP. They are associated with an increased
risk of intravascular volume expansion and elevated cardiac output.
High levels of stress can lead to a dramatic increase in BP. However,
the relationship between stress and hypertension is not well
established
Ibuprofen, naproxen, diclofenac, piroxicam, and celecoxib can cause
masked hypertension, worsening of existing hypertension, or the
development of hypertension. NSAIDs’ use increases in BP by
average of 5 mmHg and causes damage to the kidneys, heart failure,
and stroke.

Hypertension is the most important modifiable risk factor for premature CVD,
being more common than other major risk factors such as cigarette smoking, diabetes,
and dyslipidemia (46). A combination of more than one risk factor with hypertension
aggravates the risk of adverse cardiovascular and cerebrovascular events (24). A BP
of 120–129/80–84 mmHg was found to be associated with a hazard ratio of 1.1 to 1.5
for cardiovascular events, and 130–139/85–89 mmHg with a hazard ratio of 1.5 to 2.0
(47). Excessive BP on the artery walls can damage the blood vessels and lead to organ
damage. Uncontrolled BP can lead to stroke, myocardial infarction, heart failure,
aneurysm, kidney damage, metabolic syndrome, vision loss, and dementia.
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1.1.5 Medication adherence
The World Health Organization (WHO) defined medication adherence as “the
extent to which a person’s behavior corresponds with agreed recommendations from
a health care provider” (48). Medication adherence in chronic illness is a challenging
task, and the WHO estimated that approximately 50% of the patients are non-adherent
to chronic medications (48). Hypertension is a disease with few symptoms, which
makes medication adherence even more challenging (49). A 2015 cross-sectional
study that investigated the level of medication adherence to antihypertensive drugs in
the UAE, demonstrated that adherence to antihypertensive medications was lower than
50% in the newly diagnosed hypertensive patients (50). A decline in medication
adherence over time has shown to increase the risk of stroke, myocardial infarction,
and heart failure. Low medication adherence in hypertension is associated with young
age, male sex, and mild-to-moderate BP elevation (51). There is compelling evidence
that high adherence to antihypertensive treatment results in reduction of cardiovascular
risk (52). For example, being adherent to antihypertensive treatment results in 10%
lower risk for coronary artery disease (53), 11% lower risk for heart failure (54), and
22% lower risk for cerebrovascular disease (55). Apparent low medication adherence
is a common cause of uncontrolled BP.
1.1.6 Hypertension control
Although numerous effective drugs and drug classes are available to control
BP, the control rates are suboptimal (56). Several international studies have reported
the global and regional variations in hypertension control (32,56–58). While between
48% and 65% of treated patients are well controlled in North America and Europe
(57), control rates in the Middle East and South Asia are lower than 20% (32). This
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rate is only the tip of the iceberg. Findings from the Prospective Urban Rural
Epidemiology (PURE) study conducted on 17 countries, including the UAE,
confirmed that the overall hypertension control in the Middle East population was 19%
and, in the UAE, it was only 14% (34). The NESH-UAE 1998 study demonstrated the
BP control among hypertension treated population was 45% (30). As illustrated by
several surveys in the UAE, about three-fourth of patients whose BP values are
consistently above goal levels do not have medication started, and for those on
antihypertensive medications, the BP control was between 26% to 41% (32,34).
In contrast with the USA, Europe, UK, and Canada, there are limited
contemporary data of treatment inertia and the control of BP after the treatment
initiation in the UAE population. This is surprising since CVD remains the primary
cause of death in the UAE, the mean age of patients with CVD in the UAE is 50 years.
There is a general agreement that the absence of BP control reflects the burden of
uncontrolled hypertension, and their BP values exhibit the recommended targets of the
above-mentioned guidelines. Years of research have clarified that hypertensive
individuals who fail to control the BP (therapeutic inertia) and are less adherent to
prescribed lifestyle and antihypertensive medications, have a low rate of BP control
and ultimately increase their risk of confronting adverse events. Thus, faster BP control
at the early stage of hypertension provides cardiovascular protection, and better
adherence to prescribed medications can help achieve target BP values. Therefore,
improving BP control is of fundamental importance for cardiovascular prevention
worldwide.
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1.1.7 Treatment-resistant hypertension
In 2018, the AHA defined resistant hypertension or treatment-resistant
hypertension (TRH) as BP that remains above goal despite the patient adhering to the
maximum tolerated doses of three different antihypertensive medication classes, one
ideally being a diuretic (59). The latest ESC/ESH guidelines defined TRH as office
BP goal (> 130/80 mmHg or > 140/80 mmHg) despite being treated with at least three
antihypertensive drugs, including angiotensin-convertase enzyme inhibitors (ACEi) or
angiotensin-receptor blockers (ARBs), a calcium channel blocker (CCB), and a
diuretic (DU) medication (11). Thus, assessing the adherence to prescribed therapy is
a critical aspect of understanding the success or failure of hypertension management
during their early hypertension stage. Moreover, patients with TRH are potential highrisk subsets and at high risk for adverse CV events. Unfortunately, the epidemiological
evidence of TRT has been poorly characterized in the literature. Prevalence estimates
suggest anywhere from 3% to 30% of the patients require three or more medication to
achieve their BP control (60), and around 12% to 18% of the hypertensive population
have TRH (61,62). Most of the TRH studies are from western countries and lack
longitudinal BP data. However, the epidemiological evidence of TRH in the Middle
East is yet to be explored.
1.2 Statement of problem
Hypertension is a significant public health problem worldwide and is
recognized as a major modifiable risk factor for CVD (24). It is estimated that over 10
million deaths occur every year due to high BP (23). A 20 mm-Hg increase in SBP
and/or a 10 mm-Hg increase in DBP is associated with an increased two-fold risk of
death from stroke, heart disease, and other vascular diseases (45). BP reading can vary
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to a great extent; a single elevated BP reading is not sufficient to establish the diagnosis
of hypertension. Guidelines recommend using ABPM or HBPM at different time
intervals to confirm the diagnosis of hypertension (9–16). Nevertheless, BP-lowering
treatment is important as it delays the progression of the disease and can reduce the
risk of CVD. A three-month delay in the treatment of hypertension in high-risk patients
is associated with a two-fold increase in CV morbidity and mortality (45). A systematic
review and meta-analysis on adherence to antihypertensive drugs highlighted that
nearly half of newly diagnosed hypertensive patients are non-adherent to their
medications (63). Non-adherence to antihypertensive medications is identified as the
most prominent cause of uncontrolled BP and adverse outcomes (63,64).
The UAE is undergoing rapid and complex demographic and epidemiological
transition (65). With a population of 9.27 million, the age-standardized hypertension
prevalence was 33% in 2019 (32); less than half (47%) of them were on treatment, and
the control group comprised only 19% (66). However, most of the research has focused
on awareness, prevalence, treatment, and control of hypertension at the community
level (32–35,58). For instance, Shah et al. conducted a cross-sectional questionnairebased study on South Asian male expatriates seeking employment in Al Ain city (35).
They concluded that a high proportion of these immigrants had high BP. More
recently, the May Measurement Month (MMM) screening program in the community
focused on mass screening and improved awareness regarding high BP in the UAE
(66). Moreover, studies investigating the level of medication adherence to
antihypertensive drugs in the UAE are very limited, and a 2015 study reported
suboptimal (50%) medication adherence to antihypertensive medications (50).
Most of the literature involving studies conducted in the UAE is cross-sectional
(33–38,66), and the majority of the studies do not include the representative
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population. These factors limit our ability to understand the trajectories of
hypertension from diagnosis, treatment modalities, extent of BP control,
complications, adherence to antihypertensive medications, and adverse outcomes.
Research in the UAE has primarily focused on identifying the determinants for BP
control (41), associations with CVD risk factors (39,67–73), such as diabetes
(31,39,67–70), obesity (69,71–73), lifestyle factors (39) among immigrant workers
(35,72), local population (73), and workers (67). However, these existing studies do
not sufficiently examine the achievement of BP goals and trajectories of hypertension
among the UAE population. This is important because antecedent hypertensive
patients are at a higher risk of developing acute myocardial infarction (AMI). The
INTERHEART study reported a hypertension prevalence ranging from 31% to 59%
across 52 countries that includes six Arabian Gulf countries (74). In the Gulf Registry
of Acute Coronary Events (Gulf RACE), of 8,169 patients with acute coronary
syndrome (ACS), nearly half (49.4%) were reported to have hypertension (75). The
authors concluded that hypertension is associated with a higher risk profile for
increased mortality (12.7%) in ACS patients and increased risk for development of
heart failure (19.7%). Furthermore, the UAE-ACS study on 1,842 patients from four
tertiary care hospitals identified that around over one-third (34.6%) of young ACS
patients (mean age 50.8 ± 10 years) had hypertension and highlighted hypertension as
an important modifiable risk factor causing premature CVD in the UAE population
(76).
Despite extensive knowledge about ways to prevent and treat hypertension,
taking control of BP to improve quality of life has been put under the spotlight and is
currently suboptimal due to inadequacies in prevention and diagnosis. In 2016, the
LANCET took an initiative to form a commission on hypertension for identifying key
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actions to improve the management of BP and investigate the deleterious
consequences of high BP in the younger population (77). In general, hypertension is a
chronic disease, and its control demands patient self-management, which includes
monitoring BP levels, taking medications, and maintaining a healthy lifestyle.
Adherence to antihypertensive medications is pivotal for the therapeutic success of BP
control, reduction in treatment cost, and the subsequent improvement in quality of life
and clinical outcomes (78). In 2015, a cross-sectional study in Ajman assessed
medication adherence to antihypertensive medications using the Morisky Medication
Adherence Scale (MMAS-4). The study identified that nearly half (45.6%) of the
patients with hypertension were non-adherent to medications, but most of the included
population was in the older age group (> 60 years) (50). Moreover, no studies have
investigated the prevalence or incidence of TRH in the Middle East. There is a scarcity
of published data regarding the status of hypertension in clinically confirmed patients
in outpatient settings in Abu Dhabi, UAE. A comprehensive assessment of clinical
aspects in a representative sample could help us to understand the dynamics of
hypertension in the UAE population.
1.3 Literature review
Epidemiological evidence on opportunistic screening for hypertension in the
general population and BP control among those treated patients is essential to provide
the baseline monitoring and inform the development of new strategies for improving
hypertension control in the UAE. Although previous reviews in the Middle East
focused on investigating the prevalence of hypertension and its risk factors in the
Arabian population, they did not incorporate most of the studies conducted on the UAE
population (79,80). Thus, a comprehensive review of the studies conducted in the UAE
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is required to understand the hypertension prevalence in apparently healthy adult
subjects and identify the level of BP control among those treated.
This literature review is divided into three parts. The first part elaborates the
prevalence of hypertension. The second part illustrates the control of hypertension in
the UAE adult population. This part also focuses on the global prevalence and
incidence of resistant hypertension in treated hypertensive population. The third and
the last part presents the level of adherence to antihypertensive medications in the UAE
and Middle East countries.
1.3.1 Methodology of the review
A comprehensive systematic search was conducted on PubMed/MEDLINE,
Web of Science, Embase (Ovid® interface), and Google Scholar databases to identify
population-based studies.
•

Prevalence of hypertension in the UAE from January 1, 1995 to May 31, 2021.

•

Blood pressure control in the UAE: January 1, 1995 to May 31, 2021.

•

Adherence to antihypertensive medications in the Middle East: January 1,
1998, to May 31, 2021.

•

Global prevalence of TRH in treated hypertensive population: January 1, 2010,
to May 31, 2021.
A combination of Boolean operations such as AND, OR, and NOT in

combination with Medical Subject Headings (MeSH) truncation (*) with text words
were used to search titles and abstracts. All the identified articles were screened and
studies fulfilling the eligibility criteria were considered for a full-text review.
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1.3.2 Prevalence of hypertension in the UAE
1.3.2.1 Eligibility criteria
Population-based prospective studies conducted on apparently healthy adult
subjects living in the UAE and defined hypertension using the guideline-recommended
BP cut-off ≥130/80 mmHg or ≥140/90 mmHg were considered. Studies provided
estimates of the prevalence of hypertension by screening the general population. Multicountry studies were included if data on the prevalence of hypertension in the UAE
could be distinctly extracted. Only peer-reviewed full-length research articles
published in the English language were considered.
1.3.2.2 Exclusion criteria
•

Studies where standard methods for measurement of hypertension were not
clearly described. Studies conducted on diseased populations (other than
hypertensives), hospitalized patients, children, and pregnant women were
excluded.

•

Editorials, correspondence, conference proceedings, abstracts, non-human
studies, interventional studies, hospital-based studies, and expert reviews were
excluded.

•

Studies with unclear outcome measures, articles with missing or insufficient
data were excluded.

•

The updated Preferred Reporting Items for Systematic reviews and Metaanalysis 2020 (PRISMA) guideline was used to identified records, screening
of titles and abstracts accompanied by evaluation of eligibility of full texts for
final inclusion (81).

22
1.3.2.3 Overview of the included studies
A total of 1,038 articles from initial searches were retrieved in various
databases. After removing 176 duplicates and 998 irrelevant titles, 50 studies were
found eligible for a full-text review. Amongst these, 35 were excluded with reasons:
16 studies were conducted on diseased patients, eight studies did not provide the
outcome of interest estimates, three were reviews, one study was conducted on
children, and seven did not meet the inclusion criteria. Finally, 15 studies conducted
between January 1, 1995 to May 31, 2021, were included in the review (29,30,32–
34,38,58,66,72,82–87). Figure 3 illustrates the methodology for identification of
pertinent studies.

Figure 3: PRISMA 2020 flow diagram for literature search
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1.3.2.4 Characteristics of included studies
The included studies comprised a total of 139,907 participants (63.5% male)
from Abu Dhabi (n = 5, 33.3%), Dubai (n = 5, 33.3%), one from Ras Al Khaimah (n
= 1, 6.6%), and four studies were conducted on different emirates (26.6%). All the
studies were cross-sectional and predominantly conducted on the general public (n =
13, 86.6%). In addition, the majority of the studies were conducted in community
settings (73.3%), and the overall mean age was 37.2 ± 11.3 years. These characteristics
are summarized in Table 5.
Table 5: Characteristics of included studies (n = 15)
Author (year)

Location

Yusufali et al. (2017)
Al Faisal et al. (2017)

Seven
emirates
Dubai
Abu
Dhabi, Al
Ain, and
Sharjah
Seven
emirates
Dubai
Dubai

Shah et al. (2015)

Al Ain

Yusufali et al. (2015)

Dubai

Yusufali et al. (2020)
Hussain et al. (2019)
Alzaabi et al. (2019)

Yusufali et al. (2019)

Quraishi et al. (2013)
Baynouna et al. (2013)
Chow et al. (2013)
Hajat et al. (2012)
Al-Sarraj et al. (2010)
El-Shahat et al. (1999)
El Mugamer et al.
(1995)
CS: cross-sectional

Ras Al
Khaimah
Al Ain
Dubai
Abu
Dhabi
Al Ain
Abu
Dhabi, Al
Ain,
Sharjah
Abu
Dhabi

Study
design

Setting

Population

Sample
size

Mean age
(years)

CS

Health centers

General public

31,316

36.8±11.4

CS

Household

General public

3,289

-

CS

Medical
examination
centers

Men

33,327

21.6

Community

General public

6,193

38.2±13.1

CS
CS
CS

Community
Community

General public
General public
South Asian
Immigrants

917
3,716

49.5±10.3
-

1,375

34

CS

Community,
hospital

General public

4,128

38.4±11.4

Kerala market

General public

74

-

CS
CS
CS

Community
Community

General public
General public

817
918

49.1±10.2

Community

General public

50,138

36.8±14.3

CS
CS

Hospital

UAE citizens

227

31.2±8.9

Community

General public

3150

-

Community

General public

322

-

CS

CS

CS

Community
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1.3.2.5 Prevalence of hypertension
All the 15 studies used automatic and/or manual sphygmomanometer to record
the BP in the population surveyed and defined hypertension as BP ≥ 140/90 mmHg,
except Hussain et al.’s study, which applied a cut-off of > 130/80 mmHg (82). Studies
estimated the prevalence of hypertension in the UAE, ranging from 9% (83) to 52%
(34,58,87). In Abu Dhabi, studies estimated the prevalence of hypertension was
between 21% (41) to 52% (87), and 24% (84) to 52% (34) in Dubai. Only one study
was conducted on a small sample size (n = 74) visiting the Kerala market in Ras Al
Khaimah (85) and reported that half of the population studied had elevated BP (≥
140/90 mmHg). Furthermore, four studies were multi-regional studies in which two
studies included populations from seven emirates (32,66) and the other two conducted
on the general public from Abu Dhabi, Al Ain, and Sharjah (30,83). Multi-regional
studies reported a prevalence ranging from 9% (83) and 37% (30). However, Shah et
al. (35) and Alzaabi et al. (83) included only the male population attending medication
examination centers. Further details are succinctly encapsulated in Table 6.
Table 6: Prevalence of hypertension in the UAE from 1995 to 2021
Author
Yusufali et al. (61)
Hussain et al. (55)
Alzaabi et al. (56)
Yusufali et al. (39)
Yusufali et al. (39)
Al Faisal et al. (59)
Shah SM et al. (62)
Yusufali et al. (63)
Quraishi et al. (60)
Baynouna et al. (47)
Chow et al. (64)
Hajat et al. (65)
Al-Sarraj et al. (58)
El-Shahat et al. (23)
El Mugamer et al. (22)

Year
2020
2019
2019
2019
2019
2017
2015
2015
2013
2013
2013
2012
2010
1999
1995

Screened
population
31,316
3,289
33,327
6,193
917
3,716
1,375
4,128
74
817
918
50,138
227
3150
322

BP device
Automated
/Manual
Manual
Manual
Automated
Automated
Manual
Automated
Automated
Manual
Manual
Automated
Automated
Automated
Manual
Manual

Evaluation criteria
(BP reading)

Prevalence
(%)

≥140/90 mmHg

19.9

>130/80 mmHg
≥140/90 mmHg
≥140/90 mmHg
≥140/90 mmHg
≥140/90 mmHg
≥140/90 mmHg
≥140/90 mmHg
≥140/90 mmHg
≥140/90 mmHg
≥140/90 mmHg
≥140/90 mmHg
≥135/85 mmHg
≥140/90 mmHg
≥140/90 mmHg

25.1
9.2
30.2
51.9
24.0
30.5
30.5
50.0
20.8
52.0
23.1
51.5
36.6
25.2
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1.3.3 Blood pressure control in hypertensive-treated patients in the UAE
Six cross-sectional studies were identified through literature review and
reported the BP control among those treated in the UAE (30,32,34,35,38,66), see Table
7.
Table 7: Level of BP control among hypertensives in the UAE
Author

Year

Location

Yusufali et al. (66)

2020

Yusufali et al. (32)

Hypertension
Treated

Control

Seven emirates

11,681

7,077 (60.6%)

2019

Seven emirates

3,499

1,420 (40.6%)

Yusufali et al. (34)

2017

Dubai

239

62 (25.9%)

Shah et al. (35)

2015

Al Ain

667

55 (8.2%)

Yusufali et al. (38)

2015

Dubai

600

290 (48.3%)

El-Shahat et al. (30)

1999

Abu Dhabi, Al Ain,
Sharjah

334

150 (44.9%)

The overall sample size of the study population ranged from 239 (34) to 11,681
(66). Shah et al. (35) conducted on immigrant men and reported that only 8.2% of
those treated had their BP under control. In 2019 and 2020, Yusufali et al. (32,66)
screened more than 15,000 hypertensive subjects on treatment as a part of MMM.
Findings from the 2020 MMM study indicated that around 60% of those treated had
their BP under control. Studies conducted on hypertensive population with diabetes
and other comorbidities are highly extensive and beyond the thematic purview of this
dissertation.
1.3.4 Comparison of prevalence and control of hypertension in the GCC countries
To benchmark hypertension prevalence and control in the UAE, pooled
estimates from the different UAE studies were compared to country-specific estimates
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of the NCD-RisC study (57) published in Lancet 2021. NCD-RisC analyzed the data
of 1201 nationally representative surveys across 200 countries from 1990 to 2019
across to their income and reported the hypertension prevalence, awareness, treatment,
and control. For the review, country-specific data related to prevalence and control in
Arabian Gulf countries – Bahrain, Kuwait, Oman, Qatar, and Saudi Arabia were used.
The comparison of hypertension prevalence and control in the UAE and five Gulf
Cooperation Council (GCC) countries is presented in Figure 4 (57).

Figure 4: Prevalence and control of hypertension in the UAE and other GCC
countries
1.3.5 Adherence to antihypertensive medications in the Middle East
A literature review was conducted by using the PubMed/MEDLINE databases.
A manual search was also applied to identify additional articles from the reference lists
of key articles. A number of articles were found on adherence to antihypertensive
medications in the Middle East but only two in the UAE. No longitudinal studies were
found on hypertensive population in the Middle East. The search strategy was based
on the terms: adherence, compliance, medication-compliance, medication adherence,
and antihypertensive therapy. These keywords were combined using Boolean
operators as appropriate. Around 235 articles were identified. After deduplication,
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titles and abstracts of 210 studies were screened, and 29 studies were downloaded and
reviewed for a full-text review. Finally, 22 articles fulfilled the inclusion criteria. To
eliminate search bias, another researcher adopted the same search procedure
independently. There was no discrepancy with regard to articles retrieved. The
PRISMA 2020 flow diagram for literature search was shown in Figure 5.

Figure 5: PRISMA 2020 Flow diagram of literature search
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Key characteristics and outcomes of the studies investigating the level of
adherence to antihypertensive medications conducted in Middle East countries are
summarized in Table 8.
Table 8: Non-adherence to antihypertensive medications in the Middle East
Country

Study,
Year

Iran

4

Study
design
Crosssectional

Sample
size

Mean age
(years)

Assessment
method

1831

Kamran et al. (88)

671

-

MMAS-4

Saadat et al. (89)

280

60.3 ± 10

MMAS-8

Behnood-Rod et al. (90)

280

60.0 ± 10

MMAS-8

Sadeghi et al. (91)

600

56.4 ± 12.3

MMAS-8

Iraq

2

Crosssectional

753

Al-banna et al. (92)

418

-

Structured
questionnaire

Ismael et al. (93)

335

58.7 ± 11.9

MMAS-8

Jordan

4

Crosssectional

1116

Al-Jbour et al. (94)

273

69 ± 2.3

MMAS-4

Al-Daken et al. (95)

192

52.8 ± N/A

Hill-Bone

Goussous et al. (96)

471

59 ± 11.2

Structured
questionnaire

Abu Khudair et al. (97)

180

-

ARMS

59.3 ± 12.2

Structured
questionnaire

52 ± 14.6

MMAS-8

59 ± 12.2

MMAS-8

Lebanon

1

Crosssectional

Mohammad et al. (98)
Oman

1

210
Crosssectional

Al-Noumani et al. (99)
Palestine

1

Al-Ramahi et al. (100)

210

45
45

Crosssectional

450

Non-adherence
% (95% CI)
57
(42 – 72)
76
(72 – 79)
51
(45 – 57)
50
(44 – 56)
51
(47 – 55)
29
(4 – 62)
12
(9 -15)
46
(41 – 51)
30.5
(27 – 34)
13
(9 – 17)
8
(4 – 12)
24
(20 – 28)
77.2
(70 – 83)
22
(16 – 28)
22
(17 – 29)
51
(42 – 72)
51
(36 – 66)
54
(49 – 59)
54
(49 – 59)
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Table 8: Non-adherence to antihypertensive medications in the Middle East
(Continued)
Country

Study,
Year

Saudi
Arabia

8

Study
design
Crosssectional

Sample
size

Mean age
(years)

Assessment
method

1969

Non-adherence
% (95% CI)
60
(55 – 65)
66
(59 – 73)
65
(57 – 63)
55
(49 – 61)
54
(46 – 62)

Al-Sowielem et al. (101)

190

50 ± 11.7

Structured
questionnaire

Elbur et al. (102)

144

-

MMAS-4

Shaik et al. (103)

282

52 ± 12.0

MMAS-8

Khayyat et al. (104)

204

59 ± 12.2

MMAS-8

Alotayfi et al. (105)

262

-

Structured
questionnaire

67
(62 – 73)

Alqarni et al. (106)

108

-

Alkhamis et al. (107)

372

53 ± 12.4

Abdelhalim et al. (108)

402

54.1 ± 10.7

Structured
questionnaire
Structured
questionnaire
Structured
questionnaire

67
(58 – 76)
49
(44 – 54)
60
(56 – 65)
49
(45 – 52)
48
(41 – 55)
46
(39 – 52)

UAE

2

Crosssectional

453

Fahey et al. (109)

203

52. ± N/A

MMAS-4

Bader et al. (50)

250

44 ± 5.6

MMAS-8

CI: confidence interval; MMAS: Morisky medication adherence scale; ARMS: adherence to refills and
medications scale; UAE: United Arab Emirates

Numerous studies in the Middle East (50,90–110) have explored adherence to
antihypertensive treatment. All the studies are cross-sectional, used structured
questionnaires or adherence scales, and were published between 1998 (101) and 2019
(107,108). Overall, the level of adherence to antihypertensive medication in the Middle
East was suboptimal, and over half of the hypertensive patients in Saudi Arabia (60%),
Iran (57%), Palestine (54%), and Oman (51%) were non-adherent to antihypertensive
medications. In the UAE, the level of adherence to medication was only 50% (50,109).
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1.3.5.1 Focus on the UAE
Two studies were conducted in the UAE (50,109) and assessed the adherence
to medications using four-item (109) and eight-item (50) Morisky medication
adherence scale (MMAS). The overall medication adherence was only 51% and
around half of the hypertensive patients were not adherent to antihypertensive
treatment.
In 2006, Fahey et al. (109) conducted a study on 203 patients attending two
outpatient health centers in Abu Dhabi, and the medication adherence was assessed
using self-reported medication adherence recall in the past three months. Ninety
percent were Arabs, and their mean age was 52 years. The median time since the
hypertensive treatment was 5.1 years (range: 0.19–27.4 years). Overall, 52% (n = 103)
reported adherence to hypertensive medication using the MMAS-8 scale, and the
reason for non-adherence from the doctor's point of view was “forgetfulness.”
On the whole, for those who were adherent to antihypertensive treatment, the
BP target achievement (JNC VI criteria, 140/90 mmHg or 135/85 mmHg for diabetes)
was 52% versus 48% in non-adherent patients. The findings of the study revealed that
practical assessment of adherence and drug management would greatly benefit if the
physicians incorporated medication assessment in their routine practice.
Bader et al. (50) conducted a cross-sectional study in Ajman, UAE, and
assessed the predictors of non-adherence to antihypertensive medications in 250
randomly selected hypertensives attending outpatient clinics. Medication adherence
was assessed using the MMAS-4 scale and reported that the level of non-adherence
was 45.6%. In this study, 70% of the study participants were expatriates, and the mean
age of the study population was 44 ± 5.6 years. In addition, this study reported several
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predictors of adherence to antihypertensive medications as sociodemographic,
therapy-, patient-, and healthcare-related predictors.
Sociodemographic predictors include males being more likely to be nonadherent to antihypertensive medications (P = 0.01) than females and patients with
two or more children who were more likely to be non-adherent to antihypertensive
treatment than patients with no or a single child (P = 0.03).
Disease status and medication-related predictors such as those hypertensive
patients with more than one hospital admission had a higher rate of non-adherence to
antihypertensive medications (P = 0.04). Patients on two or more antihypertensive
medications were more likely to be non-adherent (P = 0.05). Hypertensive patients
who believed that the cost of the medications was high (P < 0.001) and used traditional
remedies (P < 0.001), were strongly associated with non-adherence to antihypertensive
therapy.
The patient-related factors, such as forgetfulness, being aware of hypertension
complications, and identifying their hypertensive medication, were significantly
associated with non-adherence to antihypertensive medications (P < 0.01).
Patients who lost their clinic follow-up for more than a month (P < 0.001),
attended patient counseling sessions (P < 0.001), frequently changed physicians (P =
0.02), and were already well aware of physician’s instructions (P = 0.01) were more
likely to be non-adherent to antihypertensive medications.
Bader et al.’s (50) study recommended that using adherence questionnaires in
hospitals can aid in identifying patients who are non-adherent to antihypertensive
medications.
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1.3.6 Treatment-resistant hypertension
Comprehensive reviews of the literature on global, regional, and national
prevalence and incidence of TRH are already available in the literature (110–112).
Judd et al. (110) review published literature and obtained data of TRH in North
America and Europe from 1990 to 2010. They combined the data of more than 600,000
hypertensive patients data and reported the prevalence of TRH was 10.1% among
individuals treated for hypertension and 7.9% in all hypertensives. In 2014, Achelrod
et al. (111) conducted a systematic review and meta-analysis by pooling 20
observational and four randomized controlled trials (RCTs) comprising 961,035
hypertensive population. The pooled prevalence of observational studies was 13.7%
(95% CI: 11.2–16.2) and 16.3% (10.6–21.9) in RCTs, respectively. The study also
demonstrated no differences in the TRH prevalence in males (15.3%, 95% CI: 12.5–
18.1) and 15.6% (95% CI: 13.6–17.6) in females. Most recently, in 2019, Noubiap et
al. (112) reviewed all the articles published from 1991 to 2017 and pooled the data of
3.2 million patients with hypertension on antihypertensive drugs globally. This study
included 91 studies, and most of the included studies used office blood pressure
measurement (OBPM). The pooled prevalence was stratified into three sections and
provided pooled prevalence of true-resistant hypertension, apparent TRH, and pseudoresistant hypertension. The pooled prevalence of apparent TRH was 14.7% (95% CI:
13.1–16.3).
A brief review of epidemiological research conducted on the hypertensive
population published between 2010 and May 31, 2021, was summarized in this thesis.
Cross-sectional and cohort studies treated for hypertension were considered. Fifty-five
articles identified and reported the prevalence of TRH, but there was only one article
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in the Middle East – Israel (113). No literature was found regarding TRH in the UAE.
A summary of global, regional, and national prevalence of TRH is presented in Table
9.

Table 9: Prevalence of treatment-resistant hypertension from 2010 to May 31, 2020.
Location

Study design

Global
Multinational

Prospective

Africa

Settings

Male (%)

Mean age

BP measurement

Sample size

TRH cases

-

52.6

60.2

ABPM, HBPM, OBPM

3,528,043

346,707

Hospital

61.3

69

OBPM

53530

6790

-

53.4

48.2

ABPM, OBPM

9120

1331

Algeria

Prospective,
Retrospective

Hospital

55.4

54.7

ABPM, OBPM

4542

293

Burkina Faso

Prospective

Unclear

39.7

54.8

ABPM

692

91

DR.Congo

Retrospective

Hospital

52.1

56

ABPM

636

75

Ethiopia

Prospective

Hospital

58.9

46.2

OBPM

338

29

Ghana

Prospective

Hospital

58.8

23.3

OBPM

2912

550

-

54.7

60.4

OBPM

127,233

18,678

Asia
China

Retrospective

Hospital

55.8

62.2

OBPM

2011

286

India

Retrospective

Hospital

62

51.2

OBPM

6262

1170

Prevalence
(95% CI)
15
(14 – 16)
13
(12 – 13)
13
(8 – 18)
11
(10 – 12)
13
(11 – 16)
12
(10 – 15)
9
(6 – 12)
19
(18 – 20)
16
(14 – 19)
14
(12 – 15)
19
(18 – 20)
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Table 9: Prevalence of treatment-resistant hypertension from 2010 to May 31, 2020 (Continued)
Location

Study design

Settings

Male (%)

Mean age

BP measurement

Sample size

TRH cases

Korea

Retrospective

Hospital

53.2

61.1

OBPM

6010

541

Pakistan

Prospective

Hospital

53.8

61.3

OBPM

687

226

Sri Lanka

Prospective

Hospital

50.2

61

OBPM

277

53

Taiwan

Prospective, Retrospective

Hospital, Population

50.3

61

OBPM

112263

16455

-

53.3

63.2

ABPM, HBPM, OBPM

1,537,561

125,921

Europe
Multinational

Retrospective

Population

52.6

58.5

ABPM, OBPM

1312

423

France

Retrospective

Hospital

58

62

HBPM, OBPM

144

8

Georgia

Retrospective

Hospital

55

66.6

OBPM

1756

268

Germany

Prospective, Retrospective

Population, Unclear

-

-

ABPM, HBPM

2869

370

Greece

Prospective, Retrospective

Hospital

44.7

57.8

OBPM

3721

777

Prevalence
(95% CI)
10
(8 – 12)
32
(28 – 35)
19
(15 – 24)
15
(14 – 15)
16
(13 – 19)
32
(30 – 35)
6
(3 – 11)
15
(14 – 17)
13
(12 – 15)
18
(17 – 19)
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Table 9: Prevalence of treatment-resistant hypertension from 2010 to May 31, 2020 (Continued)
Prevalence
(95% CI)
19
(4 – 33)
25
(24 – 25)
10
(8 – 12)
17
(17 – 18)

Location

Study design

Settings

Male (%)

Mean age

BP measurement

Sample size

TRH cases

Italy

Prospective, Retrospective

Hospital, Population

70.1

59.2

ABPM, OBPM

2259

361

Poland

Prospective

Unclear

41

63.6

OBPM

12375

3060

Spain

Prospective, Retrospective

Hospital, Population

51.5

67.8

ABPM, HBPM, OBPM

130470

15598

Sweden

Retrospective

Hospital

44

69

OBPM

53090

9185

UK

Retrospective

Population

-

-

OBPM

1,317,290

92811

7 (7 – 7)

-

-

-

OBPM

172432

15104

9 (9 – 9)

Unclear

-

-

OBPM

172432

15104

9 (9 – 9)

50.0

61.8

HBPM, OBPM

1,627,272

178,748

15
(12 – 19)

-

Unclear

56.2

66.3

OBPM

14684

1870

13
(12 – 13)

Middle East
Israel

Retrospective

North America
Multinational

Retrospective
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Table 9: Prevalence of treatment-resistant hypertension from 2010 to May 31, 2020 (Continued)
Location

Study design

Canada
USA

Retrospective
Prospective, Retrospective

Settings
Population
Hospital, Population

South America

Male (%)
49.9

Mean age
-

BP measurement
OBPM

Sample size

TRH cases

677

82

49.3

61.3

HBPM, OBPM

1611911

176796

32.5

62

ABPM, HBPM, OBPM

895

135

Argentina

Retrospective

Hospital

32.5

66.6

HBPM

289

29

Brazil

Prospective

Hospital

-

57.3

ABPM, OBPM

606

106

Prevalence
(95% CI)
12
(10 – 15)
15
(12 – 19)
14
(12 – 17)
10
(7 – 14)
17
(15 – 21)

TRH: treatment-resistant hypertension; CI: confidence interval; ABPM: ambulatory blood pressure monitoring; HBPM: home-based blood pressure monitoring; OBPM: officebased blood pressure monitoring.
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1.4 Study aims and objectives
1.4.1 Aims
To assess the BP management, adherence to antihypertensive medications, and
factors associated with poor BP control in newly diagnosed hypertensive patients in
the UAE.
1.4.2 Objectives
1. To assess the changes in the BP within first six months of treatment initiation
and compare the achievement of BP targets recommended by the current
international guidelines.
2. To identify the factors that are associated with the achievement of BP treatment
targets with the recommendations of each of the guidelines: ACC/AHA,
ESC/ESH, NICE, and ISH.
3. To assess the level of adherence to antihypertensive treatment and identify the
factors associated with adherence to antihypertensive medications.
4. To assess the occurrence of TRH and PRH within the first six months of
antihypertensive treatment initiation.
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Chapter 2: Methods
2.1 Study design
A retrospective cohort study was conducted by reviewing the medical charts of
newly treated hypertensive patients registered in Abu Dhabi Health Services (SEHA)
clinics between January 1, 2017 and December 31, 2017, across the Abu Dhabi region,
UAE. The chart review was conducted from September 1, 2018, until October 31,
2019.
2.2 Study setting
The study setting includes all healthcare centers and outpatient clinics at
different health settings across Abu Dhabi region, under SEHA facilities and providing
chronic care to patients with hypertension. SEHA is the largest and main corporate
healthcare network in the UAE, which provides comprehensive medical care to five
million population. Throughout the Abu Dhabi region, a total of 38 SEHA health
clinics are located across primary and secondary care centers and an additional 14
auxiliary clinics are available at tertiary care centers (114).
2.3 Study population
The target population includes the national representative Emirati adult
population, newly registered for hypertensive treatment across all the SEHA clinics
during the year 2017. Each eligible patient’s data were followed for six months using
SEHA Cerner database.
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2.4 Selection of subjects
The subjects were selected retrospectively and patients with incident
hypertension, visiting outpatient health clinics to refill their antihypertensive
medications were included.
2.4.1 Inclusion criteria
The inclusion criteria were:
•

United Arab Emirates national representative patients.

•

Aged ≥18 years.

•

Newly diagnosed with hypertension during 2017.

•

Registered for hypertension treatment at SEHA facilities.

2.4.2 Exclusion criteria
•

Non-UAE nationals.

•

Patients with established hypertension and not confirmed by ABPM or HBPM
by treating physician.

•

Hospitalized hypertension patients.

•

Not on antihypertensive medications.

•

Not on follow-up for at least one-month treatment.

•

Hypertensive patients with a history of antihypertensive medication use or
hospitalization due to elevated BP in the past 12 months of the index period.

•

Patients with hemoglobinopathy disorders and/or with systemic or malignant
disease (needs special consideration).

•

Significant renal impairment (plasma creatinine concentration >2.0 mg/L).
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2.5 Sample size collection
The minimum number of subjects to include in this study was determined in
order to have sufficient statistical power to detect any changes in the BP. The mean
SBP in the INTERHEART study was 132.5±11.9 mmHg and DBP was 73.1±9.7 (74).
The mean SBP in our study group was 133.8±17.1 mmHg and DBP was 72.3±12.7
mmHg.
•

By considering the type-I error (α) of 5% (0.05) (indicating a 5% chance that a
significant difference is actually due to chance and may not represent the true
difference).

•

The probability of type-II error (β) (not detecting a difference when one actually
exists).

•

Study power as P = 1 − β, with a 20% (0.2) chance that a significant difference
may be missed.

Calculated the sample size as per the formula
SBP

DBP

Where N= sample size of study population
μ0= mean level of BP in INTERHEART

β = probability of type-II error

study

(usually 0.2)

μ1= assuming the mean BP in this study

α

=

probability

(usually 0.05)

of

type-I

error
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σ = variance of BP in INTERHEART z = critical Z value for a given α or β
study
As the data was collected retrospectively, a post-hoc power calculation for
correlations and t-tests was performed using G*Power software (115) (Figure 6).
First, the effect size of study population in the INTERHEART study was calculated
using the formula:

The effect size of the INTERHEART case-control study was 0.1063 (74).
By using the t-test correlation: Point biserial model
Input

Tail(s)

= 1

Effect size |ρ|

= 0.1063

α err prob

= 0.05

Power (1-β err prob)

= 0.95

Non-centrality parameter δ

= 3.2933208

Critical t

= 1.6464643

Df

= 947

Total sample size

= 949

Actual power

= 0.9501298

Output

43

Figure 6: Power sampling method
2.6 Study measurements
The entire data collected at baseline and follow-up are summarized in Table 10.
Table 10: Summary of key data variables includes
Sociodemographic
Age (years)
Gender (Male/female)
Weight (kg)
Body mass index (kg/m2)
Past medical and medication history
Clinical characteristics
SBP (mmHg)
Heart rate (beats/minute)

Registered clinical setting
Height (cm)
Waist circumference (cm)
Smoking status (yes/no)

DBP (mmHg)
Date of hypertension diagnosis
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Table 10: Summary of key data variables includes (Continued)
Diabetes (yes/no)

Type of diabetes (Type 1 and Type 2)

Fasting blood glucose (mmol/l)

Glycated hemoglobin A1c (%)

Dyslipidemia (yes/no)

Serum creatinine (µmmol/L)

List of antihypertensive medications

Diabetic medications

Duration of treatment (days
prescribed)
Outcome variables
Changes in the BP
Hospitalization

Medication adherence
(Proportion of days covered)
Mortality
Non-adherence

The proportion of days covered (PDC) is a widely adopted approach used to
assess the medication adherence using medication refilling rate (116). The PDC
calculation is based on the fill dates and days’ supply for each fill of a prescription i.e.,
the number of days between the first fill of the medication during the measurement
period and the end of the measurement period. A PDC threshold level of about 80% is
considered adherent to medications and has a reasonable likelihood of achieving the
most clinical benefits (116).
2.7 Data collection procedure
The study used the Cerner® health care databases managed by SEHA facilities
to obtain the data. These extensive, electronically linked health data pertained to the
UAE residents covered by provincial health insurance. The data for the study were
collected from the health clinics and included cardiology, endocrinology, and
nephrology clinics across SEHA facilities in the UAE. Patient data, including
demographics, clinical, and other variables related to the study objective, were
collected from the patients’ electronic medical records (EMR) in Cerner database. All
the collected information was carefully cross-checked with the patients’ Financial
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Identification Number (FIN) for pharmacy claims linked to the medical record number
(MRN) for each patient.
2.8 Ethical considerations
Ethical approval was obtained from the Al Ain Hospital Research Ethics
Committee (AAHEC-08-18-103) prior to the initiation of the study. The obtained data
were considered anonymous and no personal information was collected.
2.9 Timeline
The study included patients newly diagnosed and registered for hypertension
treatment between January 1, 2017 to December 31, 2017 with a follow-up period of
six months for each patient. The retrospective data collection was performed from
September 1, 2018, until October 31, 2019.
2.10 Data analysis and statistical tests
Statistical analysis was performed using the statistical software package SPSS
for Windows version 24 (IBM Corp., Armonk, New York, USA). Baseline
characteristics and follow up data for six months are described using summary
statistics, and all outcome events were recorded and summarized individually as
proportions and 95% CIs. Statistical significance was set as two-sided P ≤ 0.05.
Objective 1: To assess the changes in the BP within first six months of treatment
initiation and to compare the achievement of BP targets recommended by the current
international guidelines.
•

Categorical variables were presented as frequency and percentages.

•

Mean ± standard deviation (SD) was used for continuous variables.
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•

Changes in the BP parameters from baseline to six-month follow-up across
different groups for categorical variables were assessed using chi-square test
and ANOVA or Kruskal–Wallis test was used for continuous variables, as
appropriate.

•

BP measurements were stratified according to the ACC/AHA 2017, ESC/ESH
2018, NICE UK 2019 and ISH 2020 guidelines and the level of BP goal
achievement were compared in accordance with these guidelines.

•

Data were presented as proportions with 95% CI.

Objective 2: To identify the factors that are associated with the achievement of BP
treatment targets according to the guidelines-recommended BP targets, see Table 2.
•

BP control at six months is first categorized according to the guidelinerecommended BP targets, see Table 2.

•

Factors independently associated with the changes in BP in 6-month follow-up
were determined using Wilcoxon signed-rank test and Mann-Whitney U test
or Kruskal-Wallis test, as appropriate.

•

Univariate and multivariate logistic regression analysis was performed to
identify the factors associated with increasing the likelihood of achieving BP
targets according to each guideline.

•

Odds ratios (OR) with 95% CI were calculated.

Objective 3: To assess the level of adherence to antihypertensive treatment, its effect
on BP control and to identify the factors associated with adherence to antihypertensive
medications.
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•

Adherence to medications was assessed according to PDC (≥80% as adherent
and <80% non-adherent).

•

Factors independently associated with the changes in BP at six-month followup between adherent and nonadherent groups were determined using the
Mann-Whitney U test or Kruskal-Wallis test, as appropriate.

•

Non-adherence as an outcome measure was used in the regression analysis and
defined as PDC <80% at six-months follow-up.

•

Covariate that influences adherence such as age, type of health setting, body
mass index and smoking were evaluated and used as reference categories.

•

Crude and adjusted OR with 95% CI were calculated.

Objective 4: To assess the occurrence of TRH and PRH within the first six months of
antihypertensive treatment initiation.
•

A decision tree algorithm model was used to determine the occurrence of TRH
and PRH in the study cohort.
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Chapter 3: Results
3.1 Study cohort
At first, hypertensive patients comprising 178,335 aged 18-100 years
registered for the treatment across SEHA facilities from 2011 to June 2018 were
identified. Of these, those who are taking at least one antihypertensive medication from
January 1, 2011, until December 31, 2016, were identified. Those newly diagnosed
patients and first dispensed of an antihypertensive medication from January 1, 2017,
were considered index date. To ensure that selection only included newly-treated
individuals, patients for whom one or more prescriptions of hypertensive medications
or hospitalization due to hypertension before the index date were excluded. A total of
12,297 patients with incident hypertensive patients and on treatment were identified
through ICD-10 code I10 (essential hypertension) as primary diagnoses were
considered. Finally, because the purpose of the study was to determine the guidelinesrecommended BP management and medication adherence in the UAE nationals,
patients with insufficient follow-up data (n = 2143), expatriates (n = 4740), and died
(n=106) were excluded. The remaining patients constituted the study cohort. More
details are in Figure 7.

49

Figure 7: Consort flow diagram of the cohort studies
A total of 5308 patients with incident hypertension were registered across 52
health centers-SEHA facilities in the emirates of Abu Dhabi between January 1, 2017,
and December 31, 2017, and had a follow-up data of 6-months. The distribution of
subjects stratified by age is shown in Table 11.
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Table 11: Distribution of hypertensive subjects by age and gender
Age group (years)

Male

Female

Total

Total

2459 (46.3%)

2849 (53.7%)

5308 (100%)

18 – 40

285 (5.4%)

251 (4.7%)

536 (10.1%)

41 – 50

654 (12.3%)

629 (11.9%)

1283 (24.2%)

51 – 60

969 (18.3%)

1267 (23.9%)

2236 (42.1%)

61 – 75
>75

397 (7.5%)
154 (2.9%)

517 (9.7%)
185 (3.5%)

914 (17.2%)
339 (6.4%)

Although the sample does not represent the whole UAE population, it captured
a good proportion of incident hypertensives across Abu Dhabi. The completeness of
the data was above 85% for BMI (n = 4588), height (n= 4703), weight (n = 4868).
However, data for some clinical parameters, such as HbA1c (n = 4501), serum
creatinine (n = 400) and dyslipidemia (n = 2007) data were incomplete. The rest of the
data regarding sociodemographics, antihypertensive treatments, and BP parameters
were complete.
Overall, the mean age of the study cohort was 53.8 years (SD± 11.5) with a
mean BMI of 31.2 (SD± 7.5) kg/m2. At baseline, the mean SBP was 133.9 ± 17.1
mmHg and DBP was 72.9 ± 12.7 mmHg. The baseline characteristics of the study
cohort according to the BP levels are illustrated in Table 12.
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Table 12: Characteristics of the study population according to the BP levels at baseline
Characteristics
Number (%)
Age, Mean (±SD)

Total
5,308
(100.0)
54.8
(±11.5)

<120 and
<80

120–129 and 130–139 or
<80
80–89

≥140 or
≥90
1,377
2,099 (39.5)
(25.9)
54.8
54.5 (±10.9)
(±12.1)

958 (18.0)

874 (16.5)

55.2
(±11.8)

55.3 (±11.9)

Gender, n (%)
2,459
Men
(46.3)
2,849
Women
(53.7)
Health center location, n (%)
2,595
Rural
(48.9)
2,713
Urban
(51.1)
Healthcare setting, n (%)
3,189
Primary
(60.1)
795
Secondary
(15.0)
1,324
Tertiary
(24.9)
Smoking, n (%)
1,883
Smoker
(35.5)
3,425
Nonsmoker
(64.5)
BMI (kg/m2),
31.2 (±7.5)
Mean (±SD)
720
Missing
(13.6)
Diabetes, n (%)
4,437
No
(83.6)
871
Yes
(16.4)

P-value

0.164
0.223

422 (44.1)

391 (44.7)

996 (47.5)

650 (47.2)

536 (55.9)

483 (55.3)

1,103 (52.5) 727 (52.8)
0.662

479 (50.0)

412 (47.1)

1,027 (48.9) 677 (49.2)

479 (50.0)

462 (52.9)

1,072 (51.1) 700 (50.8)
<0.001

468 (48.9)

488 (55.8)

1,388 (66.1) 845 (61.4)

220 (23.0)

135 (15.4)

243 (11.6)

197 (14.3)

270 (28.2)

251 (28.7)

468 (22.3)

335 (24.3)
0.955

346 (36.1)

313 (35.8)

740 (35.3)

484 (35.1)

612 (63.9)

561 (64.2)

1,359 (64.7) 893 (64.9)

30.6 (±6.8) 30.6 (±6.3)

31.6 (±8.4)

31.4 (±6.9) 0.001

159 (16.6)

116 (13.3)

236 (11.2)

209 (15.2)

796 (83.1)

730 (83.5)

1,167
1,744 (83.1)
(84.7)

162 (16.9)

144 (16.5)

355 (16.9)

0.590

210 (15.3)

BMI: body mass index, SD: standard deviation

At baseline, overall, 26% of the subjects had a BP of ≥140 or ≥90 mmHg, and
higher BP was observed in women (52.8%), nonsmokers (64.9%), and the non-DM
population (84.7%). However, significant differences in the BP levels were observed
according to their BMI and the type of health setting.
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At baseline, there were 28.4%, 29.2%, 29.2%, and 24.6% subjects with stage
1 hypertension according to the ACC/AHA, the ESC/ESH, the NICE, and the ISH
guidelines, respectively. More details on the distribution of BP according to
international guidelines are shown in Figure 8.
80
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NICE 2019

ESC/ESH 2018
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38.3

40
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18.0 20.3

35.7
24.6

28.4 29.2 29.2
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24.6
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6.3 6.6
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Figure 8: Distribution of BP according to international guidelines at baseline
From the day of diagnosis of hypertension, over 8.7% of newly diagnosed
hypertensive patients were hospitalized and 63 (1.2%) patients died within six months
due to various medical reasons. Different classes of antihypertensive drugs were
prescribed as monotherapy (71.5%) or combination therapy (28.4%). The class of
drugs used (missing data 0.3%) are shown in Figure 9.

ACEi/ARBs (31.4%)
ACEi/ARBs+CCBs (18.1%)
ACEi/ARBs+Diuretics (10.2%)
Alfa-blockers (0.8%)
Beta-blockers (15.4%)
Calcium-channel blockers (17.5%)
Diuretics (6.0%)
Vasodilators (0.3%)

Figure 9: Antihypertensive drug classes prescribed
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The majority (77.6%) had taken one antihypertensive medication, whereas 189
(3.6%) patients had taken three or more classes of antihypertensive medications
concurrently for at least one month. Higher medication use was significantly
associated with old age. The baseline characteristics of the study cohort based on the
number of antihypertensive medications given are listed in Table 13.
Table 13: Characteristics of study cohort with number of antihypertensive medications
given at baseline
Characteristics

Total
(N = 5308)

Age, Mean ±SD
54.8 ±11.5
Gender, n (%)
Men
2,459 (46.3)
Women
2,849 (53.7)
Health center location, n(%)
Rural
2,595 (48.9)
Urban
2,713 (51.1)
Healthcare setting, n(%)
Primary
3,189 (60.1)
Secondary
795 (15.0)
Tertiary
1,324 (24.9)
Smoking, n(%)
Smoker
1,883 (35.5)
Nonsmoker
3,425 (64.5)
2
BMI (kg/m ),
31.2 ± 7.4
(n = 4583, 86.3%)
<18.5
41 (0.9)
18.5–25
631 (11.9)
25–30
1485 (28)
>30
2483 (45.7)
Diabetes, n (%)
No
4,437 (83.6)
Yes
871 (16.4)
Baseline systolic BP,
133.9 ± 17.1
mmHg
Baseline diastolic
72.9 ± 12.7
BP, mmHg

Number of antihypertensive medications
One
Two
Three
4117, 77.6%
1002, 18.9%
189, 3.6%
54.0 ± 11.5
57.1 ± 11.2
59.3 ± 11.4
1906 (35.9)
2211 (41.7)

454 (8.6)
548 (10.3)

99 (1.9)
90 (1.7)

2012 (37.9)
2105 (39.7)

492 (9.3)
510 (9.6)

91 (1.7)
98 (1.8)

2494 (47)
588 (11.1)
1035 (19.5)

582 (11)
176 (3.3)
244 (4.6)

113 (2.1)
31 (0.6)
45 (0.8)

1406 (26.5)
2711 (51.1)

393 (7.4)
609 (11.5)

84 (1.6)
105 (2.0)

31.2 ± 7.6

31.0 ± 6.5

31.2 ± 6.9

32 (0.7)
500 (10.9)
1148 (25)
1889 (41.2)

8 (0.2)
114 (2.5)
280 (6.1)
454 (9.9)

1 (0)
17 (0.4)
57 (1.2)
83 (1.8)

Pvalue*
<0.001
0.201

0.970

0.126

0.001

0.824

0.001
3403 (64.1)
714 (13.5)

863 (16.3)
139 (2.6)

171 (3.2)
18 (0.3)

134.0 ± 17.1

133.8 ± 17.2

134.4 ± 18.4

0.962

73.1 ± 12.6

72.2 ± 12.9

71.9 ± 12.9

0.061

*chi-square test for categorical variables and ANOVA or Kruskal-Wallis test for continuous variables
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3.2 Blood pressure at baseline and at 6-month across the study cohort
At 6-month follow-up, a significantly higher BP reduction was observed in
men (SBP: –1.68 mmHg and DBP: –1.15 mmHg) than women (SBP: –0.84 mmHg),
and no significant reduction in the DBP (0.22 mmHg) was observed in women.
Moreover, a significant reduction in the SBP was observed in the 41-75 years age
group, and those aged 61-75 years showed higher SBP difference from baseline (–1.82
mmHg) than other age groups. Those hypertensives treated at primary care settings
showed a significant re-duction in the SBP by –2.31 mmHg (P <0.001) and DBP by –
2.15 mmHg (P <0.001), with no such reduction in SBP and DBP in those treated at
secondary and tertiary care settings, as shown in Table 14.
Table 14: Mean BP at baseline and at 6-month according to the subgroups
Systolic blood pressure
Baseline
6-months
133.9
132.7
(133.5 – 134.4)
(132.3 – 133.2)

Diastolic blood pressure
Baseline
6-months
72.9
72.5
(72.6 – 73.3)
(72.1 – 72.8)

133.8
(133.1 – 134.5)
134.1
(133.4 – 134.7)

132.1
(131.5 – 132.8)
133.2
(132.6 – 133.8)

74.3
(73.8 – 74.8)
71.7
(71.2 – 72.1)

73.2
(72.7 – 73.6)
71.9
(71.4 – 72.3)

134.7
(133.2 – 136.1)
133.2
41-50
(132.3 – 134.1)
134.0
51-60
(133.3 – 134.7)
134.5
61-75
(133.4 – 135.7)
133.5
>75
(131.6 – 135.5)
Health center location
133.9
Rural
(133.2 – 134.5)
134.0
Urban
(133.4 – 134.7)

133.3
(132.5 – 134.1)
131.8
(130.9 – 132.7)
133.0
(132.3 – 133.7)
132.7
(131.6 – 133.8)
132.5
(130.6 – 134.4)

75.2
(74.0 – 76.4)
75.3
(74.6 – 75.9)
72.6
(72.1 – 73.1)
71.6
(70.8 – 72.4)
65.8
(64.5 – 67.1)

74.5
(73.4 – 75.7)
74.0
(73.3 – 76.7)
72.5
(72.0 – 73.0)
70.8
(70.1 – 71.5)
67.9
(66.6 – 69.3)

132.8
(132.1 – 133.4)
132.7
(132.0 – 133.3)

73.0
(72.5 – 73.5)
72.8
(72.3 – 73.0)

72.5
(72.1 – 73.0)
72.4
(71.9 – 72.9)

Characteristics
Overall
Sex
Men
Women
Age (years)
18-40
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Table 14: Mean BP at baseline and at 6-month according to the subgroups
(Continued)
Healthcare setting
Primary
Secondary
Tertiary

135.3
(134.8 – 135.9)
130.7
(129.5 – 132.0)
132.5
(131.6 – 133.5)

133.0
(132.4 – 133.6)
131.7
(130.6 – 132.9)
132.5
(131.6 – 133.5)

75.6
(75.3 – 76.0)
66.5
(65.6 – 67.5)
70.1
(69.4 – 70.9)

73.5
(73.1 – 73.9)
69.9
(69.0 – 70.8)
71.6
(70.9 – 72.3)

130.3
(124.7 – 135.9)
131.7
(130.3 – 133.0)
134.0
(133.1 – 134.8)
134.7
(134.0 – 135.4)

130.1
(123.5 – 136.7)
131.5
(130.1 – 132.9)
132.4
(131.6 – 133.2)
133.8
(133.2 – 134.5)

65.8
(62.1 – 69.5)
70.6
(69.6 – 71.6)
73.7
(73.1 – 74.4)
74.1
(73.6 – 74.6)

66.6
(61.9 – 71.3)
70.8
(69.8 – 71.7)
73.0
(72.4 – 73.6)
74.2
(73.5 – 74.7)

133.7
(132.9 – 134.5)
134.1
(133.5 – 134.7)

132.4
(131.6 – 133.1)
132.9
(132.3 – 133.5)

73.0
(72.4 – 73.5)
72.8
(72.4 – 73.3)

72.2
(71.7 – 72.8)
72.6
(72.2 – 73.1)

133.1
(131.9 – 134.2)
134.1
(133.6 – 134.6)

132.8
(131.6 – 133.9)
132.7
(132.2 – 133.2)

73.3
(72.4 – 74.1)
72.8
(72.5 – 73.2)

72.5
(71.7 – 73.4)
72.5
(72.1 – 72.8)

BMI (kg/m2)
<18.5
18.5-25
25-30
>30
Smoking
Smoker
Non-smoker
Diabetes
Yes
No

BMI: body mass index

3.3 Changes in the blood pressure within the first six months of treatment
initiation
At 6-month follow-up, the mean SBP was 132.7 ± 16.9 mmHg, and DBP was
72.5 ± 12.4 mmHg. A significant average reduction in SBP of -1.68 mmHg (95% CI:
-2.46 – -0.91; P < 0.001), and DBP of -1.15 mmHg (95% CI: -1.69 – -0.60; P < 0.001)
was observed in men. For women, a significant reduction was observed in SBP of 0.84 mmHg (95% CI: -1.57 ‒ -0.12, P = 0.046), but not in DBP (0.22 mmHg) (95%
CI: -0.29‒0.73, P = 0.795). Significant changes were observed in the average changes
in DBP and SBP between men and women (P < 0.001, P = 0.035, respectively).
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Moreover, significant differences in SBP (P < 0.001) and DBP (P < 0.001) were
observed across healthcare settings. Those hypertensive patients treated at primary
care settings showed a significant reduction in the SBP by -2.31 mmHg, (95% CI: 2.99 – -1.63; P < 0.001) and DBP by -2.15, (95% CI: -2.60 – -1.70; P < 0.001);
however, no such differences in SBP were observed for patients treated at secondary
and tertiary care settings, as shown in Table 15. Moreover, no significant differences
in SBP and DBP were observed between the groups and the healthcare center location,
BMI, smoking status and DM status.
Table 15: Changes in the BP at 6-month follow-up across the study subjects
Characteristics

Change in SBP

Pvalue*

Sex
Men
Women

-1.68
(-2.46 to -0.91)
-0.84
(-1.57 to -0.12)

-0.81
(-2.48 to 0.85)
-1.39
41–50
(-2.46 to -0.32)
-1.03
51–60
(-1.83 to -0.22)
-1.82
61–75
(-3.15 to -0.49)
-1.07
>75
(-3.30 to 1.15)
Health center location
-1.11
Rural
(-1.87 to -0.35)
-1.35
Urban
(-2.09 to -0.61)
Healthcare setting
-2.31
Primary
(-2.99 to -1.63)
1.01
Secondary
(-0.36 to 2.37)
0.02
Tertiary
(-1.05 to 1.09)

Change in DBP
-1.15
(-1.69 to -0.60)
0.22
(-0.29 to 0.73)

<0.001
0.046

Age (years)
18–40

Pvalue**
0.035

Pvalue*
<0.001
0.795

0.951

0.012
-0.72
(-1.96 to 0.52)
-1.25
(-2.03 to -0.47)
-0.09
(-0.64 to 0.45)
-0.81
(-1.74 to 0.11)
2.17
(0.63 to 3.70)

0.262
0.013
0.006
0.016
0.246

0.289
0.002
0.244
0.104
0.027

0.713
0.004
<0.001

0.912
-0.46
(-0.99 to 0.06)
-0.37
(-0.90 to 0.16)

<0.001
<0.001
0.144
0.877

Pvalue**
<0.001

0.039
0.068
<0.001

-2.15
(-2.60 to -1.70)
3.38
(2.34 to 4.42)
1.48
(0.69 to 2.28)

<0.001
<0.001
<0.001
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Table 15: Changes in the BP at 6-month follow-up across the study subjects
(Continued)
Characteristics

Change in SBP

Pvalue*

BMI (kg/m2)
<18.5
18.5–25
26–30
>30

-0.20
(-7.22 to 6.83)
-0.16
(-1.69 to 1.38)
-1.56
(-2.54 to -0.57)
-0.89
(-1.65 to -0.13)

Nonsmoker

0.646
<0.001
0.044

No

Pvalue*

0.401
0.007
0.939
0.259

-0.75
(-1.37 to -0.14)
-0.23
(-0.70 to 0.24)

0.004
<0.001
0.124

-0.29
(-1.57 to 0.97
-1.41
(-2.0 to -0.8)

0.121
<0.001

Pvalue**
0.077

0.630

0.838
-1.32
(-2.21 to -0.42)
-1.19
(-1.85 to -0.53)

Diabetes
Yes

Change in DBP
0.78
(-3.46 to 5.02)
0.22
(-0.89 to 1.32)
-0.74
(-1.42 to -0.05)
0.07
(-0.48 to 0.62)

0.909

Smoking
Smoker

Pvalue**
0.277

0.011
0.128
0.463

-0.73
(-1.65 to 0.19)
-0.35
(-0.76 to -0.05)

0.119
0.432

*Wilcoxon signed-rank test, ** Mann-Whitney U test, or Kruskal-Wallis test

3.4 Achievement of blood pressure goals according to international guidelines
The overall BP goal achievements at 6th months were 39.5% (95% CI: 38.2–
40.9), 43% (95% CI: 41.6–44.3), 65.7% (95% CI: 64.4–66.9), and 40.9% (95% CI:
39.5–42.3) according to the ACC/AHA, ESC/ESH, NICE, and ISH guidelines,
respectively. Figure 10 summarizes the proportion of patients achieving the BP goals
recommended by each guideline according to age strata. According to the ACC/AHA
guidelines, only 36.3% (95% CI: 34.9–37.7) of the patients aged 18–64 years reached
BP goal of <130/80 mmHg and 56.3% (95% CI: 52.9–59.6) of patients aged 65 years
or older achieved BP goal of <140/80 mmHg.
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Figure 10: Proportion of hypertensive patients achieving BP goals by age strata at 6month according to the international guidelines. *Chi-square test; ACC/AHA:
American College of Cardiology/American Heart Association; ESC: European
Society of Cardiology/European Society of Hypertension; NICE: National Institute
of Health Care and Excellence (UK); ISH: International Society of Hypertension.
The achievement of BP goals according to each guideline was stratified by age,
smoking status, BMI, and diabetes status, as presented in Table 16. At 6 months, only
31.7% of patients aged ≤40 years achieved the ACC/AHA recommended BP goal. In
comparison to the ESC/ESH, the NICE, and the ISH guidelines, among the patients,
45.4% of smokers and 37.5% of those with BMI of ≥25 kg/m2 achieved the ACC/AHA
recommended BP goal (<130/80 mmHg).
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Table 16: Percentage of adults who achieved BP goals according to the international
guidelines.
Characteristics
Age
(years)

≤40
>40

Smoking

Smoker
Nonsmoker

BMI

<25 kg/m2
≥25 kg/m2

BMI

<30 kg/m2
≥30 kg/m2

Diabetes

No
Yes

Total
(%)
536
(10.1)
4,772
(89.9)
1883
(35.5)
3,245
(64.5)
672
(12.6)
3,910
(73.6)
2,156
(47.1)
2,426
(52.9)
4,437
(83.6)
871
(16.4)

ACC/AHA
2017
31.7
(27.9 - 35.8)
40.4
(39.0 - 41.8)
45.4
(43.2 - 47.7)
36.3
(34.7 - 37.9)
44.2
(40.5 - 48.0)
37.5
(36.0 - 39.1)
41.5
(39.4 - 43.6)
35.9
(34.0 - 37.8)
39.9
(38.5 - 41.4)
37.5
(34.4 - 40.8)

ESC/ESH
2018
37.1
(33.1 - 41.3)
43.4
(42.0 - 44.8)
47.4
(45.2 - 49.7)
40.2
(38.5 - 41.8)
47.5
(43.7 - 51.2)
40.8
(39.3 - 42.4)
44.9
(42.9 - 47.1)
39.0
(37.1 - 41.0)
43.2
(41.8 - 44.7)
40.2
(37.0 - 43.5)

NICE 2019

ISH 2020

61.6
(57.4 - 65.6)
66.1
(64.8 - 67.4)
66.7
(64.5 - 68.8)
65.1
(63.5 - 66.7)
68.2
(64.5 - 71.6)
65.2
(63.7 - 66.7)
67.9
(65.9 - 69.8)
63.6
(61.7 - 65.5)
66.2
(64.8 - 67.6)
62.9
(59.7 - 66.1)

31.7
(27.9 - 35.8)
41.7
(40.3 - 43.1)
48.6
(46.3 - 50.9)
36.3
(34.7 - 37.9)
44.9
(41.2 - 48.7)
38.8
(37.3 - 40.3)
42.8
(40.7 - 44.9)
36.9
(35.0 - 38.9)
41.3
(39.8 - 42.7)
37.5
(34.4 - 40.8)

ACC/AHA: American College of Cardiology/American Heart Association; ESC/ESH: European
Society of Cardiology/European Society of Hypertension; NICE: National Institute for Health and Care
Excellence hypertension in adult guidelines; ISH: International Society of Hypertension; BMI: body
mass index.

3.5 Factors associated with the achievement of guidelines-recommended BP
targets
The factors that are significantly associated with each guideline-recommended
BP goal attainment in hypertensive patients are shown in Table 17. The unadjusted
logistic regression analysis indicated that a normal BMI of <25 kg/m2 is a significant
predictor of attaining ACC/AHA recommended BP goals (OR: 1.32, 95% CI: 1.12–
1.55). Similar findings were observed with the ESC/ESH (OR: 1.31; 95% CI: 1.11–
1.54) and ISH (OR: 1.29; 95% CI: 1.09–1.52) recommended goals. On the contrary,
ESC/ESH and NICE recommended goals were associated with secondary care settings
(OR: 1.23; 95% CI: 1.03–1.47, and OR: 1.26; 95% CI: 1.04–1.52).
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After adjusting for multiple covariates, the guidelines-recommended BP goal
was more likely to be achieved by those who maintained normal BMI and were treated
in secondary healthcare settings. Briefly, those with BMI of <25 kg/m2 were associated
with BP targets achievement recommended by the ACC/AHA (OR: 1.26, 95% CI:
1.07–1.49), the ESC/ESH (OR: 1.27, 95% CI: 1.08–1.50), and the ISH guidelines (OR:
1.22, 95% CI: 1.03–1.44). More details are shown in Table 17.

Table 17: Factors associated with the achievement of each guideline-recommended BP goals
Odds ratio (95% confidence interval)
ACC/AHA 2017
ESC/ESH 2018
Crude
Adjusted
Crude

Adjusted

NICE 2019
Crude

Adjusted

ISH 2020
Crude

Adjusted

0.44
(0.38-0.51)
1.00

0.47
(0.39-0.58)
1.00

0.54
(0.46-0.62)
1.00

0.59
(0.48-0.73)
1.00

0.92
(0.79-1.07)
1.00

1.04
(0.84-1.28)
1.00

0.33
(0.28-0.39)
1.00

0.34
(0.28-0.42)
1.00

1.06
(0.95-1.18)
Women
1.00
Health center location
1.02
Rural
(0.91-1.13)
Urban
1.00
Healthcare setting
0.96
Primary
(0.84-1.10)
1.19
Secondary
(0.99-1.42)
Tertiary
1.00
Smoking status
0.69
Nonsmoker
(0.61-0.77)
Smoker
1.00

0.99
(0.88-1.12)
1.00

1.04
(0.93-1.16)
1.00

0.97
(0.86-1.10)
1.00

1.00
(0.89-1.12)
1.00

0.95
(0.84-1.07)
1.00

1.06
(0.95-1.18)
1.00

1.00
(0.88-1.12)
1.00

0.93
(0.80-1.08)
1.00

1.04
(0.93-1.16)
1.00

0.96
(0.82-1.11)
1.00

1.07
(0.95-1.19)
1.00

0.97
(0.83-1.13)
1.00

1.01
(0.90-1.12)
1.00

0.92
(0.79-1.07)
1.00

1.09
(0.92-1.30)
1.31
(1.03-1.66)*
1.00

0.99
(0.87-1.13)
1.23
(1.03-1.47)*
1.00

1.12
(0.95-1.32)
1.32
(1.05-1.67)*
1.00

1.05
(0.92-1.20)
1.26
(1.04-1.52)*
1.00

1.15
(0.97-1.37)
1.41
(1.11-1.81)**
1.00

0.96
(0.84-1.09)
1.18
(0.99-1.42)
1.00

1.11
(0.94-1.32)
1.34
(1.05-1.70)*
1.00

0.97
(0.83-1.13)
1.00

0.74
(0.66-0.83)
1.00

0.95
(0.82-1.11)
1.00

0.93
(0.83-1.05)
1.00

0.93
(0.80-1.09)
1.00

0.60
(0.54-0.68)
1.00

0.97
(0.83-1.13)
1.00

Variable
Age
<65 years
≥65 years
Sex
Men
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Table 17: Factors associated with the achievement of each guideline-recommended BP goals (Continued)
Odds ratio (95% confidence interval)
Variable ACC/AHA 2017
Crude
Adjusted
BMI (kg/m2)
<25
1.32
1.26
(1.12-1.55)**
(1.07-1.49)**
≥25
1.00
1.00
Diabetes
Yes
0.90
1.07
(0.78-1.05)
(0.90-1.26)
No
1.00
1.00

ESC/ESH 2018
Crude

Adjusted

NICE 2019
Crude

Adjusted

ISH 2020
Crude

Adjusted

1.31
(1.11-1.54)**
1.00

1.27
(1.08-1.50)**
1.00

1.14
(0.96-1.36)
1.00

1.14
(0.96-1.37)
1.00

1.29
(1.09-1.52)**
1.00

1.22
(1.03-1.44)*
1.00

0.88
(0.76-1.02)
1.00

1.00
(0.85-1.17)
1.00

0.87
(0.75-1.01)
1.00

0.90
(0.76-1.07)
1.00

0.85
(0.74-0.99)
1.00

1.07
(0.90-1.26)
1.00

*p≤0.05, **p≤0.01, significant factors that increase the likelihood to achieve guidelines-recommended BP goals are bolded. ACC/AHA: American College of
Cardiology/American Heart Association; ESC/ESH: European Society of Cardiology/European Society of Hypertension; NICE: National Institute for Health and Care
Excellence hypertension in adult guidelines; ISH: International Society of Hypertension. Adjusted for age, type of health center, BMI, smoking.
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3.6 Level of adherence to antihypertensive treatment
After six months of treatment initiation, adherence to antihypertensive
medication was found to be 42%. A significantly higher adherence was found among
the patients taking one medication (42.8%) than those taking three or more
medications (34%). The level of adherence to the number of antihypertensive drugs
used was stratified by gender, age, type of healthcare setting, smoking status, BMI,
and DM status, as presented in Table 18. Overall, medication adherence was higher
among patients younger than 40 years (67.9%), those with DM (53.6%), those who
were treated at secondary care settings (49.1%), nonsmokers (47.8%), and those who
had a normal BMI of <25 kg/m2 (47.1%). However, significant differences in
medication adherence were observed by gender, health center location, type of
settings, and DM status.
Table 18: Adherence to antihypertensive medication across subgroups at 6-months

Characteristics

Gender
Men
Women
Age (years)
18–40
41–50
51–60
61–75
>75
Health center location
Rural
Urban

Overall
adherence

Number of antihypertensive medications
Three or
One
Two
more

P-value

n = 2223,
(41.9%)

1764 (42.8%)

395, (39.4%) 189, (33.9%)

0.011

1032 (42%)
1191 (41.8%)

821 (43.1)
943 (42.7)

180 (39.5)
215 (39.2)

31 (31.3)
33 (36.7)

0.211
0.037

364 (67.9%)
726 (56.6)
799 (35.7)
222 (24.3)
112 (33)

326 (68.2)
603 (57)
609 (36)
154 (23.2)
72 (32)

37 (63.9)
103 (57.2)
163 (34.9)
59 (28.4)
33 (36.7)

1(-)
20 (44.1)
27 (35.5)
9 (20.9)
7 (29.2)

0.696
0.246
0.912
0.280
0.668

1080 (41.6)
1143 (42.1)

850 (42.2)
914 (43.4)

201 (40.9)
194 (38)

29 (31.9)
35 (35.7)

0.135
0.037
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Table 18: Adherence to antihypertensive medication across subgroups at 6-months
(Continued)

Characteristics

Overall
adherence
n = 2223,
(41.9%)

Healthcare setting
Primary
1280 (40.1)
Secondary
390 (49.1)
Tertiary
553 (41.8)
Smoking
Smoker
587 (31.2)
Non-smoker
1636 (47.8)
Body mass index (kg/m2)
18.5–25
297 (47.1)
25–30
588 (39.6)
>30
916 (37.8)
Diabetes
No
1756 (39.6)
Yes
467 (53.6)

Number of antihypertensive medications
Three or
One
Two
more
395,
189,
1764 (42.8%)
(39.4%)
(33.9%)

Pvalue

1024 (41.1)
296 (50.3)
444 (42.9)

213 (36.6)
86 (48.9)
96 (39.3)

43 (38.1)
8 (25.8)
13 (28.9)

0.127
0.029
0.122

442 (31.4)
1322 (48.8)

125 (31.8)
270 (44.3)

20 (23.8)
44 (41.9)

0.067
0.326

238 (47.6)
462 (40.2)
733 (38.8)

53 (46.5)
109 (38.9)
153 (33.7)

6 (35.3)
17 (29.8)
30 (36.1)

0.601
0.282
0.125

1378 (40.5)
386 (54.1)

326 (37.8)
69 (49.6)

52 (30.4)
12 (66.7)

0.015
0.337

* chi-square test

3.7 Changes in the blood pressure at 6-months according to their medication
adherence
In analyzing BP changes at six-month follow-up, a significant mean reduction
in the SBP of 4.5 mmHg (95% CI: -5.4 – -3.77). and DBP of 6.0 mmHg (95% CI: -6.5
– -5.4) was observed among those who were adherent to antihypertensive treatment
compared to the nonadherent patients (SBP: 1.15, 95% CI: 0.50 – 1.79, DBP: 3.57,
95% CI: 3.14 – 4.04) (P < 0.001 for SBP and P < 0.001 for DBP). Likewise, when
comparing BP changes among patients adherent to medications at 6-month follow-up,
a significant higher SBP reduction was observed in men than women (– 5.6 mmHg
versus – 3.5 mmHg; P = 0.024), and in patients with BMI of >30 kg/m2 (– 4.4 mmHg;
P = 0.003), as shown in Figure 11. Moreover, significant (P ≤ 0.001) differences in
DBP were observed across age, sex, and BMI; however, no such differences in SBP
and DBP were observed in patients with or without DM.
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0.6

1.2

0.1

0.1

1.3

2.0

-4.5

Yes

No

DM (P = 0.892)

3.3

2.6

5.3

4.6

3.6

BMI (P = 0.003)

1.9

4.5

>30

-4.6

26-30

5.2

18.5-25

-4.4

-4.0

>75

-3.4

61-75

Age (P = 0.183)
5.1

2.8
3.5

5

4.2

Sex (P = 0.024)

10

51-60

-3.5

-0.1
41-50

-5.2

18-40

3.5

Men

-5.2

-2.7

Overall

-4.0

-3.5
Women

-5.6

-5
-10

-5.8

-5.9

-6.0

-4.7
18.5-25

-5.9

-4.2
>75

26-30

>30

Yes

No

.3

-6.6

-3.5

-5.7

-10

-6.6

-5

-5.4

0

-6.0

∆ DBP mmHg

2.7

3.3
1.1

1.1

1.1

0

-4.5

∆ SBP mmHg

5

Non-adherent
4.7

Adherent

Overall

Men

Women

Sex (P = 0.001)

18-40

41-50

51-60

61-75

Age (P < 0.001)

BMI (P < 0.001)

DM (P = 0.844)

Figure 11: Mean changes in the BP from baseline to 6–months in the subjects
according to their adherence status. BMI: body mass index; SBP: systolic blood
pressure; DBP: diastolic blood pressure; DM: diabetes mellitus.
As shown in Figure 12, optimal adherence was observed in middle-aged
categories (51-60 years) for all the different classes of antihypertensive drugs.
Moreover, younger age (18–40 years) and older age (>60 years) had low adherence to
antihypertensive therapies irrespective of the number of medications prescribed.
Among these newly diagnosed disease, the overall medication adherence was
higher in 51 – 60 years age group, particularly combination therapy of ARBs or ACEi
with DU (45% and 44.4%), and ACEi with CCBs (44.4%). In contrast, adherence to
ACEi in the 40 to 50 year age group was higher (40.1%) and it gradually decreased as
the age increase with the adherence being at 29.9% and 13% in the 51-60 years and
>60 years age group, respectively. Medication adherence to three or more
antihypertensive medication was higher in 51 – 60 year age group (42.2%) than 41 –
50 years (31.3%), 61 – 75 years (14.1%) and > 75 years (10.9%).
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16.4
5.3
4.2

44.9

40.4
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16.9

51-60 years

31.3
36.3

41-50 years

33.3
35.5
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ACEi/ARB+CCB+DU

Figure 12: Medication adherence to different classes of drugs during the first 6months of antihypertensive treatment initiation. ACEi: angiotensin-convertase
enzyme inhibitor, ARB: angiotensin-receptor blockers, CCB: calcium channel
blockers, BB: beta-blockers, DU: diuretics.
3.8 Factors associated with adherence to antihypertensive medications
Factors significantly associated with the number of medications and adherence
to antihypertensive drugs are shown in Table 19. The unadjusted logistic regression
analysis indicated that treatment at secondary care settings (OR: 1.35, 95% CI: 1.10 –
1.65), nonsmokers (OR: 2.07, 95% CI: 1.83 – 2.37), and patients with DM (OR: 1.73,
95% CI: 1.47–2.03) were significant predictors of adherence when only one
antihypertensive drug was taken. Similar findings were observed when two
medications were taken (except in secondary care setting). On the contrary,
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nonsmokers (OR: 2.30, 95% CI: 1.22–4.35) and patients with DM (OR: 4.57, 95% CI:
1.63–12.85) were associated with adherence to three or more antihypertensive drugs.
Table 19: Factors associated with adherence to antihypertensive medications
One medication
Crude
Adjusted
0.94
0.93
(0.93(0.920.95)**
.0.94)**

Variables
Age

Two medications
Crude
Adjusted
0.96
0.95
(0.94(0.930.97)**
0.96)**

Three medications
Crude
Adjusted
0.96
0.96
(0.93(0.92-1.01)
0.99)**

Sex
0.98
(0.86-1.11)

Men

Women
1
Health center location
0.95
(0.84-1.07)

Rural

Urban
1
Healthcare setting
Primary

Secondary
Tertiary
Smoking status
Nonsmoker
Smoker
BMI
(kg/m2)

1.20
(1.041.39)**
1
0.87
(0.73-1.04)
1

0.92
(0.80-1.07)

0.92
(0.78-1.09)

1.35
(1.101.65)**
1

1.45
(1.151.84)**
1

2.07
(1.832.37)**
1
0.99
(0.980.99)**

0.98
(0.761.26)
1
1.12
(0.871.45)
1
0.89
(0.651.21)
1.47
(0.992.18)
1

1
0.98
(0.970.99)**

1.70
(1.302.22)**
1
0.97
(0.950.99)**

1.27
(1.061.53)**
1

1.62
(1.132.32)**
1

1.12
(0.95-1.33)

0.95
(0.71-1.27)

1.27
(0.69-2.32)

1.54
(0.75-3.17)

1

1

1

0.91
(0.63-1.30)

0.82
(0.46-1.54)

0.62
(0.26-1.50)

1

1

1

0.89
(0.62-1.27)

1.51
(0.71-3.19)

1.57
(0.66-3.73)

1.49
(0.95-2.35)

0.85
(0.30-2.40)

0.77
(0.23-2.55)

1

1

1

1.07
(0.76-1.52)
1
0.96
(0.940.98)**

2.30
(1.224.35)**
1

1.55
(0.62-3.82)
1

1.02
(0.97-1.07)

1.02
(0.97-1.07)

4.57
(1.6312.85)**
1

3.61
(1.1111.72)*
1

Diabetes
Yes
No

1.73
(1.472.03)**
1

1.15
(0.761.73)
1

Adjusted for age, type of health center, BMI, smoking

After adjusting for multiple covariates, an increase in age and BMI was
associated with a gradual decrease in odds to adherence to one and two
antihypertensive medications. Among the patients receiving monotherapy, men (OR:
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1.20, 95% CI: 1.04–1.39), patients treated at secondary care setting (OR:1.45, 95% CI:
1.15–1.84), and DM patients (OR: 1.27, 95% CI: 1.06–1.53) were more likely to be
adherent to monotherapy. Furthermore, DM patients were 3.6 times more likely to
adhere to three or more antihypertensive medications (OR: 3.61, 95% CI: 1.11–11.72).
3.9 Occurrence of treatment-resistant hypertension and pseudo-resistant
hypertension
The mean SBP in patients with TRH was higher in those aged ≥ 65 years (151.0
± 8.2 mmHg) than those aged <65 years (146.5 ± 13.8 mmHg). For PRH patients, the
mean SBP and DBP were much higher in the older population aged ≥65 years than in
younger patients (<65 years). More details are in Table 20.
Table 20: Age-stratified mean BP of hypertensive patients with treatment-resistant
hypertension and pseudo-resistant hypertension
<65 years

≥ 65 years

Systolic BP

Diastolic BP

Systolic BP

Diastolic BP

TRH

146.5 ± 13.8 mmHg

91.0 ± 9.7 mmHg

151.0 ± 8.2 mmHg

101.0 ± 4.9 mmHg

PRH

144.2 ± 11.6 mmHg

92.3 ± 5.8 mmHg

159.5 ± 10.8 mmHg

99.4 ± 8.0 mmHg

Among a total of 189 patients taking three or more classes of antihypertensive
medications for at least one month, 64 (33.8%) patients were adherent, and 125
(66.2%) were nonadherent to therapy. Among the patients adherent to medications, 28
(14.8%, 95% CI: 10.0 – 20.7) patients aged <65 years did not reach the BP target of
130/80, and ten patients (5.3%, 95% CI: 2.5 – 9.5) aged ≥65 years had BP above
140/80. The overall prevalence of TRH was 20.1% (95% CI: 14.6 – 26.5). On the
contrary, 125 patients were nonadherent to antihypertensive treatment, 21 (11.1%,
95% CI: 7 – 16) and 25 (13.2%, 95% CI: 8.7 – 18.9) patients did not reach the BP
target of 130/80, and 140/80, respectively. These patients were classified as PRH
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(24.4%, 95% CI: 18.4 – 31.1) caused by poor medication adherence. Figure 13 presents
the 5308 patients in detail based on their baseline BP, follow-up at 6-month, and
subsequent TRH and PRH status.

Figure 13: Flowchart of study population taking ≥3 medications for at least one month and prevalence of treatment-resistant hypertension
70
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Chapter 4: Discussion
4.1 Overview
The overall purpose of this thesis was to better understand the BP management,
adherence to antihypertensive therapy, and factors potentially influencing BP control
in the newly diagnosed hypertensive cohort within the first six months of treatment
initiation. A retrospective chart review was applied to identify the target population
and address the specific objectives of the thesis. As a starting point, a comprehensive
literature search was conducted to identify the existing epidemiological evidence on
the burden of hypertension and medication adherence across different healthcare
settings in the UAE. Based on the gaps identified in the review, consecutive studies
were performed to investigate changes in the BP and achievement of guidelinesrecommended targets for BP. Following this, associated factors that could increase the
likelihood of reaching age-specific BP targets recommended by ACC/AHA 2017,
ESC/ESH 2018, NICE 2019, and ISH 2020 guidelines were examined. The level of
medication adherence to different classes of drugs during the first six months of
antihypertensive treatment initiation and its effect on BP control was assessed. The
author also evaluated the extent of TRH and PRH among a subset of patients who did
not reach BP goals despite being treated with three or more antihypertensive
medications.
Several clinical trials and meta-analyses have demonstrated that maintaining
SBP of 120 mmHg, and DBP of 80 mmHg has several benefits in reducing the risk
associated with CVD, cerebrovascular, and renal complications significantly (117–
121). Numerous efficacious medications are currently available for treating
hypertension. However, nonadherence to antihypertensive treatment is among the
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major causative factors for uncontrolled hypertension (63,122–124). Therefore, recent
clinical guidelines have evolved to recommend lower BP thresholds combined with
lifestyle changes and adherence to antihypertensive drug therapy (9–11,15). Each
guideline aimed to improve the diagnosis and control of hypertension by redefining
the optimal systolic/diastolic BP targets for treatment in line with the most recent
evidence. They also strongly emphasized the importance of medication adherence to
improve BP control (9,11,15). However, differences in these guidelines may influence
the diagnosis and treatment targets worldwide, including Arabian countries, where
most physicians follow various international guidelines. Currently, there is a lack of
data on BP management and control in the UAE and GCC countries, with only a few
community-based cross-sectional surveys focusing on this topic (described in
literature review section 1.4.4). Therefore, this dissertation has envisioned providing
novel insights into BP management, medication adherence, and factors potentially
influencing BP control after treatment initiation.
4.2 Summary of the key findings
•

The overall reduction in the SBP and DBP within 6-months of follow-up was only
-1.23 mmHg and -0.4 mmHg respectively.

•

A higher reduction in the SBP was observed in overweight (-1.56 mmHg), men (1.68 mmHg), those aged 61–75 years (-1.82 mmHg), and treated at primary care
settings (-2.31 mmHg).

•

Men (-1.15 mmHg), those aged 41–50 years of age (-1.25 mmHg), and those
treated at primary care settings (-2.15 mmHg) showed a higher reduction in the
DBP.
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•

Guidelines-recommended BP goal achievement was suboptimal, at 39.5%, 43%,
65.6%, and 40.8% according to the ACC/AHA, the ESC/ESH, the NICE, and the
ISH guidelines, respectively.

•

The attainment of guidelines-recommended BP targets (<130/80 mmHg) among
younger patients (≤40 years), smokers, overweight and obese, and among patients
with diabetes was dramatically low.

•

Those who had a normal BMI and were treated at secondary care settings were
more likely to achieve guideline-recommended BP targets.

•

The overall adherence to antihypertensive medications was only 42%. Higher
adherence was found among the patients on monotherapy (42.8%) than those
taking two (39.4%) and ≥3 medications (34%).

•

At 6-month, a significant reduction in BP was observed in patients adherent to
medications (systolic: – 4.5 mmHg and diastolic: – 5.9 mmHg) than those who
were nonadherent to antihypertensive therapy (SBP increased by 1.15 mmHg and
DBP by 3.59 mmHg).

•

Among the patients who were adherent to medications, higher SBP reduction was
observed in men than women (– 5.6 mmHg versus – 3.5 mmHg), and in patients
with BMI of >30 kg/m2 (– 4.4 mmHg)

•

A higher reduction in the DBP was observed in those aged 61–75 years (– 9.3
mmHg), men (– 6.6 mmHg), and overweight and obese (– 5.9 mmHg and – 5.8
mmHg) patients exhibiting good medication adherence.

•

A DM diagnosis was associated with higher odds of treatment adherence to
monotherapy (OR: 1.27) and three or more antihypertensive drugs (OR: 3.61).
Patients treated at secondary care settings (OR: 1.45) and male gender (OR: 1.20)
were more likely to be adherent to monotherapy. However, an increase in age (OR:
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0.93) and BMI (OR: 0.98) was associated with lower odds of medication
adherence.
•

The overall prevalence of TRH was 20.1%, with 14.8% and 5.3% in those aged
<65 years and ≥65 years, respectively.

4.3 Blood pressure changes from baseline to six-months
The primary analysis of this thesis focused on changes in BP after six months
of antihypertensive treatment initiation. Results showed broad difference in SBP (–
1.23 mmHg) and DBP (– 0.4 mmHg) changes in six months. The magnitude of the BP
changes in six months varied across the study population based on age, gender, and
healthcare settings. To the best of our knowledge, no studies in the UAE or the Middle
East have used longitudinal data to date to investigate the BP changes in the Arabian
population. Prior studies from the Western countries demonstrated that greater visitto-visit changes in BP over time were associated with increased risk for CVD events,
irrespective of mean BP levels (125,126). A recent SPRINT ancillary study indicated
a potential for more significant differences in the mean between trial SBP participants
by – 7.3 mmHg (95% CI: – 7.6 mmHg to – 7.1 mmHg) than standard care (–4.6 mmHg,
95% CI: – 4.9 mmHg to – 4.4 mmHg) at one year (127). In addition, the differences
between the routine BPs and trial BPs are not consistent over time and also found
varied significantly by sex, history of CVD, and clinical sites. This highlights the
differences in BP measurement techniques, quality of estimates, and clinical practice
between trials and routine clinical practice. However, most of the SPRINT trial
participants were older adults (mean age: 68.5 ± 9.1 years) and had a history of CVD
(118,126). This limits our ability to generalize or translate these findings to the present
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population, who are at the early stage of hypertension, with a mean age of 54.8 ± 11.5
years.
Another interesting finding observed in this thesis was that the mean reduction
in SBP was much lower in young adults (<40 years) than in the older population.
Recent Coronary Artery Risk Development in Young Adults (CARDIA) study
demonstrated that the with mean annual increase in the SBP (per 1.03 mmHg/year)
and DBP (per 0.95 mmHg/year) was associated with an increase in CVD events by
55% (HR: 1.55, 95% CI: 1.39 – 1.73) and 43% (HR: 1.43, 95% CI: 1.25 – 1.64),
respectively. However, these results may not be generalizable due to differences in the
population (African American). Given the implications of the earlier onset of ASCVD
among young UAE nationals (<55 years) than in western countries, interventions to
control BP and other CVD risk factors should be prioritized to reduce premature CVD
events and deaths in the UAE.
4.4 Blood pressure control
Adopting a lower BP threshold for hypertension (≥130/80 mmHg) and
stringent target BP goals underlines the importance of early preventive measures and
non-pharmacological intervention. Despite this, studies continue to record inadequate
BP control (128,129) and show poor physician compliance with such guidelines (130–
132). The continental divide of guidelines-recommended BP goals is reflected in the
UAE cohort, showing variations in achievement across hypertensive subjects.
Applying the ACC/AHA criteria (<130/80 mmHg) to this study population, a
substantially lower proportion of patients (39.5%) achieved a consistent BP target
varied to the rates of the USA (46.6%) (133), Canada (41.1%) (134), and Spain
(25.1%) (135). However, when using the BP targets of the ESC/ESH, NICE, and ISH
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criteria, the achievement of BP goal was similar or lower than Italy (66.5%) (136) and
the UK (63%) (137), but higher than the 2019 global BP control (13.8%) (56).
The thesis’ findings revealed substantially low BP goal achievement
recommended by the four different guidelines across hypertensive patients of different
age groups. Furthermore, a marginal difference in the achievement of guidelinesrecommended BP goals was observed between the groups. These variations were also
reflected across all the compared guidelines. Since the underlying reasons for the
association between the groups and less improved BP control were unclear, this
putative relationship warrants further elucidation. The improved BP control among
these patients may be partly explained by the comprehensive promotion of a healthy
lifestyle, such as adequate physical activity, low saturated fat intake, low-salt meals,
and medical information provided by counselors regarding CVD risks related to
hypertension.
Hypertension in young adults is mostly latent and associated with obesity and
metabolic syndrome (79). International guidelines have paid more attention to the
management of hypertension and CVD risks in older patients (9–11), although the
long-term (>10 years) risks are higher in young adults. Also, this study found 31.7%
achievement of guidelines-recommended BP goal of 130/80 mmHg in those aged ≤40
years. Thus, improving BP control and the systematic management of cardiometabolic
risk factors in younger patients is vital to reduce the burden of atherosclerotic CVD
(ASCVD).
The notable finding of this thesis is the overall high rate of BP goal
achievement among patients maintaining normal BMI. These patients are more likely
to reach guidelines-recommended BP targets (except NICE recommendation). As
shown in the guidelines, the first step of intervention in newly diagnosed hypertensive
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patients is a lifestyle change (9–11,15). This non-pharmacological approach can
induce weight loss. A recent Cochrane review observed that a 4.0 kg reduction in body
weight reduces SBP and DBP by 4.5 mmHg and 3.2 mmHg, respectively, and
significantly reduces cardiovascular mortality (HR: 0.70, 95% CI: 0.57–0.87) in
hypertensive individuals (138). A meta-analysis of 25 randomized controlled trials
showed a reduction in BP on average by 1.05/0.92 mmHg for each kilogram of weight
loss (139). Regardless of whether BP values are above normal, a healthy diet and
lifestyle modifications should be prioritized along with adherence to pharmacological
treatment, which could ultimately lower CVD risk in the early stage of hypertension.
In this thesis, about 15% of patients were managed at secondary care settings
and were more likely to achieve the BP targets recommended by four different
international guidelines. A study conducted by Billups et al. investigated the BP
control among 86,512 hypertensive subjects in the USA by applying a BP cutoff of
<140/90 mmHg (140). They observed that the patients treated in primary care settings
were more likely to control their BP than those treated in specialty settings. The reason
for these findings is not clear, and more research is needed to understand the
determinants of BP control at an early stage of hypertension.
A significant variation in the SBP and DBP was observed across the study
population based on age, gender, and healthcare setting. No authentic data are
available from the UAE or the Middle Eastern countries to estimate the BP threshold
levels or target BP goal achievement to help reduce the CVD risk in this region,
particularly among high-risk patients. The epidemiological evidence on BP control
(<140/90 mmHg) among UAE nationals was conducted more than two decades ago
(30). Findings on the NESH-UAE conducted in 1998 demonstrated poor BP control
among known hypertensive subjects (19%), out of which only 42% were taking
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antihypertensive medications (30). Evidence from the meta-analyses showed that
lower BP targets, compared to any higher BP target, help reduce the risk of stroke,
myocardial infarction, major CV events, and heart failure (59,141–143). The study
findings suggest that the optimal BP target for patients with hypertension is still
elusive. Thus, these variables should be considered while using the international
guidelines for BP control and early CVD management in the UAE.
4.5 Medication adherence
In clinical practice, nonadherence is a common cause of antihypertensive
treatment failure and treatment resistance. In this study, out of the 5308 patients with
incident hypertension who started on hypertension treatment, adherence to
antihypertensive medications was found among 42% of the patients. A recent metaanalysis reported that the overall nonadherence to antihypertensive medications was
48% for the Asian population (95% CI: 41 – 54%) and 41% for the Middle Eastern
population (95% CI: 30 – 52) (123). Current estimates on the prevalence of adherence
to antihypertensive medication in the Middle East are based on cross-sectional studies
and self-reported questionnaires. The reported proportion of medication adherence to
antihypertensive therapy in this study (42%) is in concordance with adherence rates
reported in Arabian Gulf countries, including Saudi Arabia (40%) (108), Oman (49%)
(99), and two studies in the UAE (52% and 54%) (50,109). This study has the
advantage of accounting for longitudinal BP control and medication adherence using
detailed pharmacy information among a large, community cohort of patients with
incident hypertension.
Another important finding of this thesis is the evaluation of the BP changes
among patients adherent to antihypertensive treatment compared to the nonadherent
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patients. Focusing on BP changes is important to understand the implications of
medication adherence on BP control in incident hypertensive patients. Analysis of BP
changes indicated that patients adherent to treatment had a significant reduction in BP
than those nonadherent to antihypertensive therapy (Figure 11). This numeric
difference in BP indicates a clinically meaningful effect of adherence on BP control.
Thus, monitoring medication adherence on each visit can be used as a therapeutic tool
and significantly improve BP control. Educating patients regarding positive changes
in diet and lifestyle in standard care coupled with improved adherence to
antihypertensive medication can have an absolute improvement in BP control.
4.6 Treatment-resistant hypertension
Nonadherence to antihypertensive medications is among the most common
reasons for uncontrolled blood pressure and a significant cause of TRH. The degree of
nonadherence to medications and prevalence of TRH remains unknown in the Arabian
population. Guidelines defined TRH as the patients who did not reach BP targets
despite taking three or more antihypertensive medications for at least one month
(11,59). In general, patients adherent to ≥3 classes of antihypertensive medications but
not reaching the BP goals are called TRH. A similar scenario in nonadherent patients
is considered pseudo-resistant hypertension (PRH) (111). Thus, medication adherence
plays a significant role in defining antihypertensive treatment failure and treatment
resistance. However, most studies could not rule out PRH caused by nonadherence to
drug therapy and distinguish true TRH from PRH (111). Therefore, knowledge
regarding medication adherence after initiation of therapy, TRH among the patients
adherent to antihypertensive medications, and PRH caused by poor adherence is
essential to improve hypertension management.
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Patients with TRH have a poor prognosis and a higher risk of end-organ damage, heart
failure, cardiovascular events, and premature death (11,59,144). Few studies described
the prevalence of TRH in incident hypertensive patients (62,111,145), and a metaanalysis by Noubiap et al. reported the pooled prevalence of TRH of 14.7% (95% CI:
13.1 – 16.3) and PRH of 10.3% (95% CI: 6.0 – 15.5) (112). Based on the present study,
one in every five incident hypertensive patients taking three or more antihypertensive
medications will continue to meet TRH criteria over follow-up. In addition, the thesis
also showed that one in every four patients who were not adherent to hypertensive
treatment had PRH. According to the guidelines-recommended BP targets for different
age groups, the prevalence of TRH among patients aged 18-64 years was 14.8% and
5.3% in patients aged 65 years or older. Our overall estimates of TRH (20.1%) are
higher than global prevalence (14.7%) (112,146), but lower than Europe (32%),
Pakistan (32%) (147), and Poland 25% (148). The discrepancy is significant, and the
variation might be due to the differences in study design, target population, definitions
used, and failure to exclude suboptimal adherence, a common cause of apparent TRH.
A recent randomized trial on smartphone app intervention showed improved patient
adherence and BP control in patients with uncontrolled hypertension (149).
4.7 Association between BP goals and medication adherence with selected
baseline characteristics
Several factors at the patient level might be associated with guidelinerecommended BP goal attainment and adherence to antihypertensive therapy. These
factors may include age, sex, BMI, healthcare settings, smoking status, and diabetes.
Some researchers have hypothesized that guidelines-recommended BP control may be
strongly affected by gender (150), worsen with urbanization (151), and obesity (152).
Moreover, other studies have shown that variations in the healthcare setting (140,153)

81
and underlying CVD risk factors, such as smoking and DM, strongly influence target
BP goal attainment (9,15).
Adequate number and dose of prescribed BP medications and medication
adherence contribute to hypertension control in treated patients. Studies have shown
less than 50% adherence to antihypertensive therapy in the first year of treatment
initiation (63,64). The increase in the number of antihypertensive drugs, older age, and
family history of CVD are some of the specific factors associated with good adherence
(154,155). However, studies examining the factors affecting adherence to
antihypertensive medications in the UAE are limited (50). This thesis briefly examined
the relationship between baseline characteristics and target BP goal attainment and
adherence to antihypertensive therapy.
Findings from this thesis identified seven factors significantly and
independently associated with guidelines-recommended BP goal attainment and
medication adherence to antihypertensive therapy, including older age. This finding
contradicts prior studies that indicated that older age was associated with better
medication adherence (155,156). In contrast, those who had a normal BMI and were
treated at secondary care settings were more likely to achieve guideline-recommended
BP targets. In addition, about 15% of patients were managed at secondary care settings
and were more likely to achieve the BP targets recommended by four different
international guidelines (9–11,15). As shown in the guidelines, the first step of
intervention in newly diagnosed hypertensive patients is a lifestyle change (9–11,15).
Therefore, non-pharmacological approaches such as weight reduction can help achieve
BP control and reduce CVD risk. Another approach to improve patient outcomes is
through the patients’ medical records examination to quickly identify their risk factors
and tailor interventions for those who are not at their goals.
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The notable finding of this study is that hypertensives treated at secondary care
settings are shown to be associated with guidelines-recommended BP achievement and
better adherence. This study observed that the patients treated in secondary care
settings were more likely to control their BP than those treated in primary and tertiary
care settings. Several studies have observed adherence to antihypertensive treatment
among hypertensive patients treated at primary care but lack consistency (157–159).
A recent study from Pakistan demonstrated significant variations in the medication
adherence to hypertensives treated at primary (23.8%), secondary (38.9%), and tertiary
care settings (43.6%) (157). The plausible reasons for this in the secondary care
settings are specialty clinic settings for chronic disease, and physicians spend more
time with patients explaining the importance of BP control and improved medication
adherence.
Individuals with DM were found to have a significantly lower risk of
nonadherence to antihypertensive treatment. This finding is similar to other studies
that showed hypertensive patients with DM were more likely to adhere to medications
(155,160). This suggests that patients with concomitate comorbid conditions might be
more aware of having higher disease risk and thus exhibit better medication adherence.
4.8 Strengths and limitations
This dissertation described the extent of guidelines-recommended BP control
and medication adherence among the Emirati population across 54 health facilities in
the emirates of Abu Dhabi, UAE. This is the first study conducted among a nationally
representative sample of hypertensive patients in the UAE after the 1998 NESH-UAE
study. Therefore, our findings could reasonably compare the public health implications
of each guideline in the UAE population. Furthermore, it is essentially the first
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longitudinal study conducted among the incident hypertensive population and
described BP changes and adherence to antihypertensive therapy after treatment
initiation. Multiple clinical factors along with BP management as well as medication
adherence were analyzed, and the prevalence of TRH and PRH was estimated in a
large newly treated hypertensive cohort. The relatively large sample size and
consecutive data of both BP parameters and pharmacy refilling information permitted
robust analyses of less common but important outcomes, such as TRH and PRH.
However, like many epidemiological studies conducted on hypertension with
methodological limitations, this work encountered some limitations that need to be
considered in interpreting the results. This section will discuss the methodological
strengths and limitations of this work.
4.8.1 Study design
One of the main strengths of this thesis is the amount of data used to estimate
BP management and medication adherence. Cohort studies – either prospective or
retrospective design – are among the most powerful observational study designs to
answer various research questions reliably (161). These designs have high accuracy
and efficiency as their respective main advantage. In prospective cohort design, where
exposure is assessed at baseline, each subject is followed in time to study disease or
mortality development. In contrast, in a retrospective design, eligible subjects are
identified, a cohort is composed, and exposures are assessed at baseline. After that, the
subsequent event occurrence or death is studied during the historical observational
period. However, prospective design is expensive and time-consuming because of a
usually extended follow-up, due to which it also suffers from loss-of-follow-up. Vice
versa, retrospective design is a very time-efficient and elegant way of answering new
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questions with existing data (162). In the UAE, EMR records BP measured at the
SEHA clinics and provided a complete picture of hypertension in the population than
the coded health information collected at acute hospital discharges. Thus, a
retrospective chart review is appropriate to capture the incident hypertensives with
follow-up data to answer the research hypothesis. Furthermore, the sample size was
determined by using statistical power sampling to approve or reject the working
hypothesis and avoid random errors in the results of the research work.
4.8.2 Internal and external validity
Although cohort studies have a lower risk of presenting bias than ecological,
case-control, cross-sectional, or prevalence studies, they are not free from bias. In
general, observational studies are evaluated in terms of both internal and external
validity. Internal validity refers to the strength of the inferences from the study. That
is, did the “exposure” cause a difference in the outcome. The importance of assessing
internal validity is whether observed changes can be attributed to exposure and not to
other plausible causes. It is determined by a series of factors that can lead to systematic
errors. The bias can occur at any stage of research, such as sample selection, data
collection, or analysis. Whereas external validity is the ability to generalize study
results to a more universal population (163). Factors that allowed for the validity of
the thesis are discussed below.
a. Selection bias
Selection bias is a systematic error that occurs if the selection of the exposed
or unexposed subjects in a retrospective study is somehow related to the outcome of
interest. Since a retrospective cohort study starts after all subjects have been exposed
to the disease, they would generally know their exposure and outcome status. In
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general, selection bias is a problem when the study subjects are not a truly
representative population and might cause differences in the associations between
exposure and outcomes. Selection bias can occur in many ways, such as the loss-tofollow-up, healthy-worker bias, and non-response bias (164).
In this research, selection bias was minimized by including a representative
sample of the population from primary, secondary, and tertiary care health centers
across emirates of Abu Dhabi. The Emirati population has full health insurance
coverage and has a unique EMR and FIN number that helps capture the accurate
information of each patient during the follow-up. Furthermore, all the subjects met the
inclusion criteria and had sufficient exposure during the study period, and outcomes
data were considered.
b. Information bias
Information bias is another systematic error that could originate from the
erroneous collection of information, instruments used to assess the outcomes, or lossto-follow-up. In the retrospective design, data is collected from existing records. There
could be missing data due to poor registration quality or missing variables that are
important to assess the outcomes. To minimize the information bias in this research
work, the author considered the variables above 85% of completeness. Data of some
clinical parameters, such as HbA1c (n = 4501), serum creatinine (n = 400), and lipid
parameters (n = 2007), were incomplete and were excluded from the analyses.
Moreover, all the data were extracted at a similar time to capture appropriate and
consistent information.
To further reduce misclassification bias, all the data were collected from the
medical records using ICD-10 coding following physician confirmed cases of incident
hypertension by ABPM or HBPM and initiated antihypertensive treatment. However,
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EMR records also face erroneous and missing data, which might affect the inferences
of research. To circumvent this issue, specific sociodemographic and clinical variables
measuring similar observations were collected from the EMR.
c. Confounding
Confounders are the variables associated with the exposure and health
outcomes but not necessarily a cause of the event or outcome. The importance of
confounding is that it suggests an association that does not exist or masks a true
association. Confounding commonly occurs in observational studies and poorly
designed RCTs. The most common confounders in the epidemiological survey are age
and gender. In the cohort design, people are not randomly assigned to exposed and
unexposed groups. It is difficult to maintain both groups by certain variables, such as
age, sex, or other confounders. The authors considered important confounders
observed from previous studies and applied statistical adjustment techniques to
overcome bias and minimize confounders. Furthermore, all regression models were
adjusted for commonly interfering factors, such as age, BMI, smoking, and type of
healthcare center. However, residual confounding cannot be ruled out.
4.8.3 Limitations
The study has some limitations. First, the present study relied on automated
office BP measurements and pharmacy refill information from an electronic medical
record; however, this method for determining hypertension and medication adherence
has been widely applied in previous studies (165–167). Second, due to the study's
retrospective nature, it cannot obtain complete information regarding some of the
factors associated with guidelines-recommended BP targets achievement, including
medication-taking behavior, patient-physician interactions, physical activity, and
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some cardiometabolic risk factors, and diet, to control hypertension. Third, we did not
have data on patients with white-coat hypertension or masked hypertension. Fourth,
our data were collected from 2017–2018 across SEHA health facilities in the emirate
of Abu Dhabi, the largest emirate in the UAE, which may not represent the entire UAE.
Fifth, we did not account for optimal dosage of medications or the use of fixed-dose
combination therapy; however, medication use and dosage in the present study
represent real-world management choices. Sixth, Previous studies have indicated that
ABPM may provide more accurate estimates of TRH and be more prognostic than
routinely used office-based BP measurement (168,169). Moreover, office-based BP
measurements are routinely used in the management of hypertension. Due to the
study’s retrospective nature, we could not distinguish the white-coat effects on
apparent TRH, which might present a chance of misclassification as some patients may
use additional medications and be treated at private health facilities. Penultimately,
although the adherence was poor, we did not investigate the potential causes and
barriers to antihypertensive medication adherence. Lastly, it is hard to define the
response to treatment within six months of treatment initiation and needs more
emphasis to define TRH in the incident hypertensive population.
4.9 Implications for future research
One of the main strengths of this research is the amount of data used to explore
the perspectives of hypertension in the UAE. This research has provided a valuable
platform for future investigations around hypertension epidemiology and management
in the UAE by laying a foundation for intensifying prevention efforts in the high-risk
population.
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There was a lack of information on other important variables, such as the
family history of CVD, physical activities, dietary intake, and prescribing patterns.
Hence, a more comprehensive assessment of hypertension and its determinants among
the UAE population is needed to account for the impact of these factors on BP control.
Moreover, there is a dearth of evidence on the epidemiology of hypertension among
the Arabian Gulf population. Also, the driving force behind hypertension prevalence
remains largely unknown, even though CVD risk factors are highly pertinent in these
countries.
None of the studies from the Middle East have used ABPM or HBPM to assess
hypertension, even though guidelines recommended ABPM as a gold-standard method
for diagnosing hypertension. Moreover, no longitudinal studies are conducted to
evaluate the changes in the BP over time. Thus, more studies assessing hypertension
using prospective longitudinal studies are needed to ascertain the actual status of
hypertension in the Arabian samples. Finally, there is a need for studies to investigate
trajectories and future outcomes in the young population.
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Chapter 5: Conclusions
In conclusion to this dissertation, BP control was suboptimal across the study
population, and more than half (58%) of the patients were nonadherent to the
treatment. This research identified variations in the BP goals according to the
ACC/AHA vs. the ESC/ESH, NICE, and ISH guidelines in the UAE population. The
overall average reduction in BP within six months was only 1.23 (SBP) and 0.40
(DBP) mmHg. Patients who were adherent to an antihypertensive therapy reported a
significant BP reduction at a 6-month follow-up. About one in every five patients
taking three or more antihypertensive medications continued to meet the criteria for
TRH.
The dissertation found that hypertensive patients with normal BMI and those
who are treated at secondary care settings are more likely to reach guidelinesrecommended BP targets. Age and BMI were among the independent risk factors for
medication adherence.
These findings support the need for more extraordinary efforts toward
improving medication adherence and BP control during the early stages of
hypertension. BP control efforts should also prioritize improving cardiometabolic
goals and lifestyle changes at an early stage of hypertension. Further studies are needed
to determine the causes of nonadherence to antihypertensive treatment and the
prognosis of patients with TRH.

90
References
1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et
al. The seventh report of the joint national committee on prevention, detection,
evaluation, and treatment of high blood pressure. JAMA. 2003; 289(19): 256071.
2. Riva-Rocci S. Un nuovo sfigmomanometro Gazz. Med di Torino. Med di
Torino. 1986; 50: 981-1017.
3. Korotkov NS. A contribution to the problem of methods for the determination
of the blood pressure. Rep Imperial Milit-Med Acad St Petersburg. 1905; 11:
365-7.
4. Page IH. Pathogenesis of arterial hypertension. JAMA. 1949; 140(5): 451-458.
5. Carretero OA, Oparil S. Essential hypertension: part I: definition and etiology.
Circulation. 2000; 101(3): 329-335.
6. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern
Med. 2003; 139(9): 761-76.
7. Wolff T, Miller T. Evidence for the reaffirmation of the US Preventive Services
Task Force recommendation on screening for high blood pressure. Ann Intern
Med. 2007; 147(11): 787-791.
8. Siu AL. Screening for high blood pressure in adults: US Preventive Services
Task Force recommendation statement. Ann Intern Med. 2015; 163(10): 778786.
9. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison
Himmelfarb
C,
et
al.
2017
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
guideline for the prevention, detection, evaluation, and management of high
blood pressure in adults: a report of the American College of
Cardiology/American Heart Association Task Force on Clinical Pr. J Am Coll
Cardiol. 2018; 71(19): 2275-2279.
10. National Guidelines Center (UK). Hypertension in adults: diagnosis and
management. London: The National Institute of Health and Care Excellence
(NICE); 2019.
11. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.
2018 ESC/ESH Guidelines for the management of arterial hypertension: The
Task Force for the management of arterial hypertension of the European Society
of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur
Heart J. 2018; 39(33): 3021-3104.

91
12. Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, et
al. Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment,
prevention, and treatment of hypertension in adults and children. Can J Cardiol.
2018; 34(5): 506-525.
13. Gabb GM, Mangoni AA, Anderson CS, Cowley D, Dowden JS, Golledge J, et
al.. Guideline for the diagnosis and management of hypertension in adults—
2016. Med J Aust. 2016; 205(2): 85-89.
14. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The
Japanese Society of Hypertension guidelines for the management of
hypertension (JSH 2019). Hypertens Res. 2019; 42(9): 1235-1481.
15. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al.
2020 International Society of Hypertension global hypertension practice
guidelines. Hypertens. 2020; 75(6): 1334-1357.
16. Guirguis-Blake JM, Evans CV, Webber EM, Coppola EL, Perdue LA, Weyrich
MS. Screening for hypertension in adults: updated evidence report and
systematic review for the US Preventive Services Task Force. JAMA. 2021;
325(16): 1657-1669.
17. Hodgkinson JA, Tucker KL, Martin U, Beesley L, McManus RJ. The use of
ambulatory blood pressure measurement. Br J Hosp Med. 2015; 76(11): 631637.
18. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, et al.
Day-night dip and early-morning surge in blood pressure in hypertension:
prognostic implications. Hypertension. 2012; 60(1): 34-42.
19. Campbell NR, Lackland DT, Niebylski ML. and World Hypertension League
and International Society of Hypertension Executive Committees. High blood
pressure: why prevention and control are urgent and important—a 2014 fact
sheet from the World Hypertension League and the International Society of
Hypertension. J Clin Hypertens. 2014; 16(8): 551-553.
20. Kannel WB, Dawber TR, Kagan A, Revotskie N, STOKES III. Factors of risk
in the development of coronary heart disease—six-year follow-up experience:
the Framingham Study. Ann Intern Med. 1961; 55(1): 33-50.
21. Kontis V, Mathers CD, Rehm J, Stevens GA, Shield KD, Bonita R, et al.
Contribution of six risk factors to achieving the 25× 25 non-communicable
disease mortality reduction target: a modelling study. Lancet. 2014; 384(9941):
437-447.
22. Cohen DL, Townsend RR, Angell SY, DiPette DJ. The World Health
Organization recognizes noncommunicable diseases and raised blood pressure
as global health priority for 2025. Clin Hypertens (Greenwich). 2014; 16(9):
624-625.

92
23. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, et al. Global
burden of hypertension and systolic blood pressure of at least 110 to 115 mm
Hg, 1990-2015. JAMA. 2017; 317(2): 165-182.
24. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Global Burden of
Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood
Pressure). National, regional, and global trends in systolic blood pressure since
1980: systematic analysis of health examination surveys and epidemiological
studies with 786 country-years and 5· 4 million participants. Lancet. 2011;
377(9765): 568-577.
25. Rahimi K ECMS. The epidemiology of blood pressure and its worldwide
management. Circ Res. 2015; 116(6): 925-936.
26. GBD 2017 Risk Factor Collaborators 2018. Global, regional, and national
comparative risk assessment of 84 behavioural, environmental and occupational,
and metabolic risks or clusters of risks for 195 countries and territories, 1990–
2017: a systematic analysis for the Global Burden of Disease Stu. Lancet. 2018;
392(10159): 1923-1994.
27. Salahudeen A.. Hypertension among UAE citizens. Emirates Med J. 1987; 5:
52-58.
28. Musaiger AO, Bener A, Bin-Ishaq SA, Al-Hosani H. Cardiovascular disease in
UAE: An overview. Emirates J Food Agric. 1994;: 86-99.
29. el Mugamer IT, Ali Zayat AS, Hossain MM, Pugh RN. Diabetes, obesity and
hypertension in urban and rural people of bedouin origin in the United Arab
Emirates. J Trop Med Hyg. 1995; 98(6): 407-415.
30. El-Shahat YI, Bakir SZ, Farjou N, Hashim T, Bohaliga A, Al-Hossani H, et al.
Hypertension in UAE citizens-preliminary results of a prospective study. Saudi
J Kidney Dis Transpl. 1999; 10(3): 376-381.
31. Sabri S, Bener A, Eapen V, Abu Zeid MS, Al-Mazrouei AM, Singh J. Some risk
factors for hypertension in the United Arab Emirates. East Mediterr Health J.
2004; 10(4-5): 610-619.
32. Yusufali A, Bazargani N, Agrawal A, Muhammed K, Obaid H, Gabroun A, et
al. May Measurement Month 2017: an analysis of blood pressure screening
results from the United Arab Emirates—Northern Africa and Middle East. Eur
Heart J Suppl. 2019; 21(Supplement_D): D118-D120.
33. Hajat C, Harrison O, Al Siksek Z. Weqaya: a population-wide cardiovascular
screening program in Abu Dhabi, United Arab Emirates. Am J Public Health.
2012; 102(5): 909-914.
34. Yusufali AM, Khatib R, Islam S, Alhabib KF, Bahonar A, Swidan HM, et al.
Prevalence, awareness, treatment and control of hypertension in four Middle
East countries. J Hypertens. 2017; 35(7): 1457-1464.

93
35. Shah SM, Loney T, Sheek-Hussein M, El Sadig M, Al Dhaheri S, El Barazi I, et
al. Hypertension prevalence, awareness, treatment, and control, in male South
Asian immigrants in the United Arab Emirates: a cross-sectional study. BMC
Cardiovasc Disord. 2015; 15(1): 30. Doi: 10.1186/s12872-015-0024-2.
36. Al-Sharbatti S, Shaikh R, Mathew E, Sreedharan J, Muttappallymyalil J, Basha
S. The use of obesity indicators for the prediction of hypertension risk among
youth in the United Arab Emirates. Iran J Public Health. 2011; 40(3): 33-40.
37. Sreedharan J, Mathew E, Muttappallymyalil J, Al Sharbatii S, Shaikh RB, Basha
SA. Determinants of blood pressure among youth in Ajman, UAE. Nepal J
Epidemiol. 2010; 1(1): 17-21.
38. Yusufali A, Bazargani N, Muhammed K, Gabroun A, AlMazrooei A, Agrawal
A, et al. Opportunistic screening for CVD risk factors: the Dubai shopping for
cardiovascular risk study (DISCOVERY). Global Heart. 2015; 10(4): 265-272.
39. Baynouna LM, Neglekerke NJ, Ali HE, ZeinAlDeen SM, Al Ameri TA. Audit
of healthy lifestyle behaviors among patients with diabetes and hypertension
attending ambulatory health care services in the United Arab Emirates. Global
Health Promot. 2014; 21(4): 44-51.
40. Abdulle AM, Nagelkerke NJ, Abouchacra S, Pathan JY, Adem A, Obineche EN.
Under-treatment and under diagnosis of hypertension: a serious problem in the
United Arab Emirates. BMC Cardiovasc Disord. 2006; 6(1): 24. Doi:
10.1186/1471-2261-6-24.
41. Baynouna LM, Nagelkerke NJ, Al Ameri TA, Al Deen SM, Ali HI.
Determinants of diabetes and hypertension control in ambulatory healthcare in
Al ain, United Arab Emirates. Oman Med J.. 2014; 29(3): 234-238.
42. NCD-RisC. NCD-RisC Risk Factors Collaboration. [Online].; 2020 [cited 2020
April 14. Available from: https://ncdrisc.org/data-downloads-bloodpressure.htm.
43. Boutitie F, Gueyffier F, Pocock S, Fagard R, Boissel JP; INDANA Project
Steering Committee. J-shaped relationship between blood pressure and mortality
in hypertensive patients: new insights from a meta-analysis of individual-patient
data. Ann Intern Med. 2002; 136(6): 438-449.
44. Clark CE, Taylor RS, Shore AC, Ukoumunne OC, Campbell JL. Association of
a difference in systolic blood pressure between arms with vascular disease and
mortality: a systematic review and meta-analysis. Lancet. 2012; 379(9819): 905914.
45. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood
pressure reduction and risk of cardiovascular disease and mortality: a systematic
review and network meta-analysis. JAMA Cardiol. 2017; 2(7): 775-781.
46. Kornitzer M, Dramaix M, De Backer G. Epidemiology of risk factors for
hypertension. Drugs. 1999; 57(5): 695-712.

94
47. Talaei M, Hosseini N, Koh AS, Yuan JM, Koh WP. Association of “elevated
blood pressure” and “stage 1 hypertension” with cardiovascular mortality among
an Asian population. J Am Heart Assoc. 2018; 7(8): e008911. Doi:
10.1161/JAHA.118.008911.
48. Sabaté E, Sabaté E. Adherence to long-term therapies: evidence for action. 1st
ed. E S, editor. Geneva: World Health Organization; 2003.
49. Lagu T, Weiner MG, Eachus S, Tang SS, Schwartz JS, Turner BJ. Effect of
patient comorbidities on filling of antihypertensive prescriptions. Am J Manag
Care. 2009; 15(1): 24-30.
50. Bader RJ, Koprulu F, Hassan NA, Ali AA, Elnour AA. Predictors of adherence
to antihypertensive medication in northern United Arab Emirates. East Mediterr
Health J. 2015; 21(5): 309-318.
51. Qvarnström M, Kahan T, Kieler H, Brandt L, Hasselström J, Bengtsson Boström
K, et al. Persistence to antihypertensive drug treatment in Swedish primary
healthcare. Eur J Clin Pharmacol. 2013; 69(11): 1955-1964.
52. Kronish IM, Ye S. Adherence to cardiovascular medications: lessons learned
and future directions. Prog Cardiovasc Dis. 2013; 55(6): 590-600.
53. Perreault S, Dragomir A, Roy L, White M, Blais L, Lalonde L, et al. Adherence
level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol.
2010; 69(1): 74-84.
54. Perreault S, Dragomir A, White M, Lalonde L, Blais L, Bérard A. Better
adherence to antihypertensive agents and risk reduction of chronic heart failure.
J Intern Med. 2009; 266(2): 207-218.
55. Perreault S, Yu AY, Côté R, Dragomir A, White-Guay B, Dumas S. Adherence
to antihypertensive agents after ischemic stroke and risk of cardiovascular
outcomes. Neurology. 2012; 79(20): 2037-43.
56. Egan BM, Kjeldsen SE, Grassi G, Esler M, Mancia G. The global burden of
hypertension exceeds 1.4 billion people: should a systolic blood pressure target
below 130 become the universal standard?. J Hypertens. 2019; 37(6): 11481153.
57. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension
prevalence and progress in treatment and control from 1990 to 2019: a pooled
analysis of 1201 population-representative studies with 104 million participants.
Lancet. 2021;: S0140-6736.
58. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al.
Prevalence, awareness, treatment, and control of hypertension in rural and urban
communities in high-, middle-, and low-income countries. JAMA. 2013; 310(9):
959-968.

95
59. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, DennisonHimmelfarb CR, et al. Resistant Hypertension: Detection, Evaluation, and
Management: A Scientific Statement From the American Heart Association.
Hypertension. 2018; 72(5): e53-e90.
60. Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the
United States? Curr Opin Cardiol. 2012; 27(4): 386-91.
61. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008.
Hypertension. 2011; 57(6): 1076-80.
62. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et
al. Incidence and prognosis of resistant hypertension in hypertensive patients.
Circulation. 2012; 125(3): 1635-42.
63. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA.
Nonadherence to antihypertensive drugs: a systematic review and meta-analysis.
Medicine
(Baltimore).
2017;
96(4):
e5641.
Doi:
10.1097/MD.0000000000005641.
64. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al.
Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical
consequences. Eur Heart J. 2013; 34(38): 2940-2948.
65. Hannawi S. Salmi, IA. Health workforce in the United Arab Emirates: analytic
point of view. Int J Health Plan Manag. 2014; 29(4): 332-341.
66. Yusufali A, Bazargani N, Bin Belaila BA, Suhail AM, Shuri HH, Agrawal A, et
al. May Measurement Month 2018: an analysis of blood pressure screening
results from United Arab Emirates. Eur Heart J Suppl. 2020; 22(Supplement_H):
H128-31.
67. Bener A, Obineche E, Gillett M, Pasha MA, Bishawi B.. Association between
blood levels of lead, blood pressure and risk of diabetes and heart disease in
workers. Int Arch Occup Environ Health. 2001; 74(5): 375-378.
68. Mathew E, Ahmed M, Hamid S, Abdulla F, Batool K. Hypertension and
Dyslipidemia in Type 2 Diabetes Mellitus in United Arab Emirates. Australasian
Med J. 2011; 3(11): 699-706.
69. Hossain MM, Pugh RN, Malik M. Prevalences and correlates of diabetes,
obesity, and hyperlipidemia in the United Arab Emirates (UAE). Bahrain Med
Bull. 1998; 20(3): 119-122.
70. Al-Lawati JA, N Barakat M, Al-Zakwani I, Elsayed MK, Al-Maskari M, M AlLawati N, et al. Control of risk factors for cardiovascular disease among adults
with previously diagnosed type 2 diabetes mellitus: a descriptive study from a
middle eastern Arab population. Open Cardiovasc Med J. 2012; 6: 133-40.
71. Razzak H, El-Metwally A, Harbi A, Al-Shujairi A, Qawas A. The prevalence
and risk factors of obesity in the United Arab Emirates. Saudi J Obesity. 2017;
5(2): 57-65.

96
72. Shah SM, Loney T, Dhaheri SA, Vatanparast H, Elbarazi I, Agarwal M, et al.
Association between acculturation, obesity and cardiovascular risk factors
among male South Asian migrants in the United Arab Emirates–a cross-sectional
study. BMC Public Health. 2015; 15: 204. Doi: 10.1186/s12889-015-1568-x.
73. Mussa BM, Abduallah Y, Abusnana SJ. Prevalence of hypertension and obesity
among emirati patients with type 2 diabetes. Journal of Diab Metabol. 2016;
7(1): 1-5.
74. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of
potentially modifiable risk factors associated with myocardial infarction in 52
countries (the INTERHEART study): case-control study. Lancet. 2004;
364(9438): 937-52.
75. Ali WM, Zubaid M, El-Menyar A, Al Mahmeed W, Al-Lawati J, Singh R, Ridha
M, Al-Hamdan R, Alhabib K, Al Suwaidi J. The prevalence and outcome of
hypertension in patients with acute coronary syndrome in six Middle-Eastern
countries. Blood Press. 2011; 20(1): 20-26.
76. Yusufali AM, AlMahmeed W, Tabatabai S, Rao K, Binbrek A. Acute coronary
syndrome registry from four large centres in United Arab Emirates (UAE-ACS
Registry). Heart Asia. 2010; 2(1): 118-121.
77. Olsen MH, Angell SY, Asma S, Boutouyrie P, Burger D, Chirinos JA, et al. A
call to action and a life course strategy to address the global burden of raised
blood pressure on current and future generations: the Lancet Commission on
hypertension. Lancet. 2016; 388(10060): 2665-2712.
78. van der Laan DM EPBCBJNGHJ. Factors associated with antihypertensive
medication non-adherence: a systematic review. J Human Hypertens. 2017;
31(11): 687-94.
79. Akl C, Akik C, Ghattas H, Obermeyer CM. The cascade of care in managing
hypertension in the Arab world: a systematic assessment of the evidence on
awareness, treatment and control. BMC Public Health. 2020; 20(1): 835. Doi:
10.1186/s12889-020-08678-6.
80. Bhagavathula AS, Shehab A, Ullah A, Rahmani J. The Burden of Cardiovascular
Disease Risk Factors in the Middle East: A Systematic Review and MetaAnalysis Focusing on Primary Prevention. Curr Vasc Pharmacol. 2021; 19(4):
379-389.
81. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
PRISMA 2020 explanation and elaboration: updated guidance and exemplars for
reporting systematic reviews. BMJ. 2020; 372: n160.
82. Hussain HY, Salim NA, Tuffaha MG, Ayoub AY. Systolic and Diastolic
Hypertension Among Dubai Population, Utilizing Household Survey Data, Risk
Approach Analysis, 2019. Int J Biomed Clin Sci. 2019; 4(4): 115-120.

97
83. Alzaabi A, Al‐Kaabi J, Al‐Maskari F, Farhood AF, Ahmed LA. Prevalence of
diabetes and cardio‐metabolic risk factors in young men in the United Arab
Emirates: A cross‐sectional national survey. Endocrinol Diab Metabol. 2019; 2:
e00081. Doi: 10.1002/edm2.81.
84. Al Faisal W, Hussein H. Hypertension: Discrepancy between Enquiry and
Measurement, Understanding Blood Pressure Readings. Front Biomed Sci.
2017; 2(4): 18-22.
85. Quraishi MU, Begum S, AnshooAgarwal SC, UmmulbaneenShamji AN, Al
Akeel N, Noori MA, et al. Study to Know the Prevalence and Awareness of
Hypertension in Market Population of Ras Al Khaimah, UAE. J Basic Applied
Sci Res. 2013; 3(2): 458-462.
86. Baynouna LM, Revel AD, Nagelerke NJ, Omar A, Ahmed N. High prevalence
of the cardiovascular risk factors in Al-Ain, United Arab Emirates. Saudi Med
J. 2008; 29(8): 1173-8.
87. Al-Sarraj T, Saadi H, Volek JS, Fernandez ML. Metabolic syndrome prevalence,
dietary intake, and cardiovascular risk profile among overweight and obese
adults 18–50 years old from the United Arab Emirates. Metabol Syndr related
disorder. 2010; 8(1): 39-46.
88. Kamran A, Sadeghieh Ahari S, Biria M, Malepour A, Heydari H. Determinants
of Patient's Adherence to Hypertension Medications: Application of Health
Belief Model Among Rural Patients. Ann Med Health Sci Res. 2014; 4(6): 9227.
89. Saadat Z, Nikdoust F, Aerab-Sheibani H, Bahremand M, Shobeiri E, Saadat H,
et al. Adherence to antihypertensives in patients with comorbid condition.
Neprhourol Mon. 2015; 7(4): e29863. Doi: 10.5812/numonthly.29863.
90. Behnood-Rod A, Rabbanifar O, Pourzargar P, Rai A, Saadat Z, Saadat H, et al.
Adherence to antihypertensive medications in Iranian patients.. Int J Hypertens.
2016; 2016(1): 1-7.
91. Sadeghi N. Study of adherence to treatment & its related factors in hypertensive
patients referring to erman health centers in 1396. (Thesis). 2018. School of
Medicine. Kerman, Iran; Kerman University of Medical Sciences.
92. Al-banna HI, Saeed SM. Compliance to Antihypertensive Treatment and Causes
of Partial or Poor Compliance in Patients Attending Ali-Kamal Consultation
Center in Suliamania. Zanco J Med Sci. 2010; 14(1): 78-84.
93. Ismael Z. Compliance of Hypertensive Patients to Medication in AL-Imam ALHussein medical City-Karbala-2018. J Kerbala Med.. 2019; 11(2): 36-43.
94. Al-Jbour B, Abu Kamel A, Barhoom H. Knowledge about Hypertension and
Antihypertensive Medication Compliance in a Jordanian Community Sample. J
Educ Pract. 2013; 4(24): 81-7.

98
95. Al-Daken LI, Eshah NF. Self-reported adherence to therapeutic regimens among
patients with hypertension. Clin Exp Hypertens. 2017; 39(3): 264-70.
96. Goussous LS, Halasah NA, Halasa M. Non-Compliance to Antihypertensive
Treatment among Patients Attending Prince Zaid Military Hospital. World
Family Medicine J: Incorporat Middle East J Family Med. 2015; 99(1645): 1-5.
97. Abu Khudair S, Khader YS, Morrissey H, El-Khatib Z, Sandor J. Factors
Associated with Suboptimal Adherence to Hypertensive Medications Among
Syrian Refugees - Cross-Sectional Study at the Zaatari Camp, Jordan. Patient
Prefer Adherence. 2021; 15: 2125-2135.
98. Yassine M, Al-Hajje A, Awada S, Rachidi S, Zein S, Bawab W, et al. Evaluation
of medication adherence in Lebanese hypertensive patients. J Epidemiol Glob
Health. 2016; 6(3): 157-67.
99. Al Noumani H, Wu JR, Barksdale D, Knafl G, AlKhasawneh E, Sherwood G.
Health beliefs and medication adherence in Omanis with hypertension.. J
Cardiovasc Nurs. 2018; 33(6): 518-26.
100. Al-Ramahi R. Adherence to medications and associated factors: A crosssectional study among Palestinian hypertensive patients. J Epidemiol Glob
Health. 2014; 5(2): 125-32.
101. Al Sowielem LS, El Zubier AG. Compliance and knowledge of hypertensive
patients attending PHC centres in Al-Khobar, Saudi Arabia. East Meditarr Med
J. 1998; 4(2): 301-7.
102. Elbur AI. Level of adherence to lifestyle changes and medications among male
hypertensive patients in two hospitals in Taif; Kingdom of Saudi Arabia. J
Pharm Pharm Sci. 2015; 7(4): 168-72.
103. Shaik SA, Alsuwailem A, Alhargan A, Alswailem A, Alshiha D, AlGhalib H, et
al. Medications adherence level and its associated factors among hypertensive
patients at a major referral hospital, in Riyadh, KSA. Asian J Med Sci. 2016;
7(4): 24-30.
104. Khayyat SM, Khayyat SM, Hyat Alhazmi RS, Mohamed MM, Abdul Hadi M.
Predictors of medication adherence and blood pressure control among Saudi
hypertensive patients attending primary care clinics: a cross-sectional study.
PLoS ONE. 2017; 12(1): 255-67.
105. Alotayfi MJ, Alsohaimi SA, Al-Qadi BK, Kamil SM, Aththi AJ, Alhazmi GA,
et al. Poor compliance to anti-hypertensive drugs in Saudi Arabia. Egypt J Hosp
Med. 2018; 73(5): 6696-701.
106. Alqarni AM, Hammad AS, Alhejaili MA, Alatawi AA, Alrashedi MH, Alenezi
MF, et al. Assessment of Adherence to Hypertension Medications and
Awareness of Hypertension Medications among People with Hypertension in
Tabuk. Egypt J Hosp Med. 2018; 70(8): 1365-70.

99
107. Alkhamis AM, Alsalman AJ, Al Khamis M, Alkhamis A, Alotaibi NM.
Prevalence of nonadherence to antihypertensive medications among adults
attending primary healthcare clinics in Al-Hasa region: a cross-sectional study.
Dr Sulaiman AlHabib Med J. 2019; 1(2): 26-43.
108. Abdelhalim HN, Zahrani AI, Shuaibi AM. Factors affecting treatment
compliance of patients on antihypertensive therapy at National Guard Health
Affairs (NGHA) Dammam Primary Health Care Clinics (PHCC). J Fam Comm
Med. 2019; 26(3): 168-72.
109. Fahey M, Abdulmajeed A, Sabra K. Measurement of adherence to antihypertensive medication as perceived by doctors and patients. Qatar Med J.
2006; 15(1): 44-8.
110. Judd E, Calhoun DA. Apparent and true resistant hypertension: definition,
prevalence and outcomes. J Hum Hypertens. 2014; 28(8): 463-8.
111. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the
prevalence of resistant hypertension in treated hypertensive populations. Am J
Hypertens. 2015; 28(3): 355-61.
112. Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global
prevalence of resistant hypertension: a meta-analysis of data from 3.2 million
patients. Heart. 2019; 105(2): 98-105.
113. Weitzman D, Chodick G, Shalev V, Grossman C, Grossman E. Prevalence and
factors associated with resistant hypertension in a large health maintenance
organization in Israel. Hypertension. 2014; 64(3): 501-7.
114. Ambualtory health services. Abu Dhabi Health Services. [Online].; 2016 [cited
2018
May
15.
Available
from:
https://www.seha.ae/ahs/English/aboutus/Pages/Formation-of-AHS.aspx.
115. Faul F. G*Power software. Universitat Kiel, Germany. [Online]. [cited 2018
July 23. Available from: http://www.gpower.hhu.de/en.html.
116. Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing
terminology and definitions of medication adherence and persistence in research
employing electronic databases. Med Care. 2013; 51(8 Suppl 3): S11-21.
117. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive
blood pressure lowering on cardiovascular and renal outcomes: updated
systematic review and meta-analysis.. Lancet. 2016; 387: 435-443.
118. Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G,
et al.. Optimal systolic blood pressure target after SPRINT: insights from a
network meta-analysis of randomized trials. Am J Med. 2017; 130: 707-719.
119. Kawano H, Fujiwara A, Kai H, Kumagai E, Okamoto R, Shibata R, et al. Effects
of blood pressure lowering in patients with heart failure with preserved ejection
fraction: a systematic review and meta-analysis. Hypertens Res. 2019; 42: 504513.

100
120. Sakima A, Satonaka H, Nishida N, Yatsu K, Arima H.. Optimal blood pressure
targets for patients with hypertension: a systematic review and meta-analysis.
Hypertens Res. 2019; 42: 483-495.
121. Fei Y, Tsoi MF, Cheung BM.. Determining the optimal systolic blood pressure
for hypertensive patients: a network meta-analysis. Can J Cardiol. 2018; 34:
1581-1589.
122. Biffi A, Rea F, Iannaccone T, Filippelli A, Mancia G, Corrao G. Sex differences
in the adherence of antihypertensive drugs: a systematic review with metaanalyses. BMJ Open. 2020; 10(7): e036418. Doi: 10.1136/bmjopen-2019036418.
123. Mahmood S, Jalal Z, Hadi MA, Khan TM, Haque MS, Shah KU. Prevalence of
nonadherence to antihypertensive medication in Asia: a systematic review and
meta-analysis. Int J Clin Pharm. 2021; 43: 486-501.
124. Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to Single-Pill
Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic
Review and Meta-Analysis. Hypertension. 2021; 77(2): 692-705.
125. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, et al.
Prognostic significance of visit-to-visit variability, maximum systolic blood
pressure, and episodic hypertension. Lancet. 2010; 375(9718): 895-905.
126. Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, et
al. Visit-to-visit variability of blood pressure and coronary heart disease, stroke,
heart failure, and mortality: a cohort study. a cohort study. Annals of internal
medicine. 2015 Sep 1;163(5):329-38. Ann Intern Med. 2015; 163(5): 329-38.
127. Drawz PE, Agarwal A, Dwyer JP, Horwitz E, Lash J, Lenoir K, et al.
Concordance between blood pressure in the systolic blood pressure intervention
trial and in routine clinical practice. JAMA Intern Med. 2020; 180(12): 1655-63.
128. Alhaddad IA, Hamoui O, Hammoudeh A, Mallat S. Blood pressure control in
treated hypertensive Middle Eastern patients: a post hoc analysis based on JNC8
definitions. Vasc Health Risk Manag. 2019; 15: 35-46.
129. Zhou Y, Jia L, Lu B, Gu G, Hu H, Zhang Z, et al.. Updated hypertension
prevalence, awareness, and control rates based on the 2017ACC/AHA high
blood pressure guideline. J Clin Hypertens. 2019; 21(6): 758-65.
130. Shnaimer JA GI. Primary health care physicians' knowledge and adherence
regarding hypertension management guidelines in southwest of Saudi Arabia.
Medicine
(Baltimore).
2020;
99(17):
e19873.
Doi:
10.1097/MD.0000000000019873.
131. Ale O BR. Awareness of hypertension guidelines and the diagnosis and
evaluation of hypertension by primary care physicians in Nigeria. Cardiovasc J
Afr. 2017; 28(2): 72-76.

101
132. Teoh SH, Razlina AR, Norwati D, Siti Suhaila MY.. Patients' blood pressure
control and doctors' adherence to hypertension clinical practice guideline in
managing patients at health clinics in Kuala Muda district, Kedah. Med J
Malaysia. 2017; 72(1): 18-25.
133. Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright Jr JT, et al..
Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure
Guideline. Circulation. 2018; 137: 109-118.
134. Garies S, Hao S, McBrien K, Williamson T, Peng M, Khan NA, et al. Prevalence
of hypertension, treatment, and blood pressure targets in Canada associated with
the 2017 American College of Cardiology and American Heart Association
Blood Pressure Guidelines. JAMA Network Open. 2019; 2(3): e190406. Doi:
10.1001/jamanetworkopen.2019.0406.
135. Gijon-Conde T, Sanchez-Martinez M, Graciani A, Cruz JJ, Lopez-Garcia E,
Ortola R, et al.. Impact of the European and American guidelines on
hypertension prevalence, treatment, and cardiometabolic goals. J Hypertens.
2019; 37: 1393-1400.
136. Tocci G, Presta V, Citoni B, Figliuzzi I, Bianchi F, Ferrucci A, et al.. Blood
Pressure Target Achievement Under Monotheraphy: A Real-Life Appraisal.
High Blood Press Cardiovasc Prev. 2020; 27(6): 587-596.
137. Scholes S, Conolly A, Mindell JS. Income-based inequalities in hypertension
and in undiagnosed hypertension: analysis of health survey for England data. J
Hypertens. 2020; 38(5): 912-24.
138. Semlitsch T, Krenn C, Jeitler K, Berghold A, Horvath K, Siebenhofer A. Longterm effects of weight-reducing diets in people with hypertension. Cochrane
Database Syst Rev. 2021; 2: CD008274. Doi: 10.1002/14651858.CD007654.
139. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM.. Influence of weight
reduction on blood pressure: a meta-analysis of randomized controlled trials.
Hypertension. 2003; 42(5): 878-84.
140. Billups SJ, Saseen JJ, Vande Griend JP, Schilling LM.. Blood pressure control
rates measured in specialty vs primary care practices within a large integrated
health system. J Clin Hypertens (Greenwich). 2018; 20(9): 1253-1259.
141. Olaiya MT, Cadilhac DA, Kim J, Nelson MR, Srikanth VK, Gerraty RP, et al.
Community-based intervention to improve cardiometabolic targets in patients
with stroke: a randomized controlled trial. Stroke. 2017; 48: 2504-2510.
142. Zhang YQ, Li Y, Dong YG, Wu YH, Bian R, Li JH, et al.. A nationwide
assessment of blood pressure control and the associated factors in Chinese type
2 diabetes mellitus patients. J Clin Hypertens (Greenwich). 2019; 21(11): 16541663.
143. DeMarzo AP.. Multiple cardiovascular risk factors indicate cardiovascular
disease in stage 1 hypertension. High Blood Press Cardiovasc Prev. 2019; 26:
135-137.

102
144. Sheppard JP, Martin U, McManus RJ. Diagnosis and management of resistant
hypertension. Heart. 2017; 103(16): 1295-1302.
145. de Oliveira-Filho AD, Costa FA, Neves SJ, de Lyra Junior DP, Morisky DE..
Pseudoresistant hypertension due to poor medication adherence. Int J Cardiol.
2014; 172(2): e309-10.
146. Brambilla G, Bombelli M, Seravalle G, Cifkova R, Laurent S, Narkiewicz K, et
al.. Prevalence and clinical characteristics of patients with true resistant
hypertension in central and Eastern Europe: data from the BP-CARE study. J
Hypertens. 2013; 31(10): 2018-24.
147. Naseem R, Adam AM, Khan F, Dossal A, Khan I, Khan A, et al.. Prevalence
and characteristics of resistant hypertensive patients in an Asian population.
Indian Heart J. 2017; 69(4): 442-446.
148. Hanus KM, Prejbisz A, Gasowski J, Klocek M, Topor-Madry R, Lesniak W, et
al.. Relationship between gender and clinical characteristics, associated factors,
and hypertension treatment in patients with resistant hypertension. Kardiologia
polska.. 2017; 75(5): 421-31.
149. Morawski K, Ghazinouri R, Krumme A, Lauffenburger JC, Lu Z, Durfee E, et
al. Association of a smartphone application with medication adherence and
blood pressure control: the MedISAFE-BP randomized clinical trial. JAMA
Intern Med. 2018; 178(6): 802-9.
150. Ramirez LA, Sullivan JC. Sex differences in hypertension: where we have been
and where we are going. Am J Hypertens 2018; 31:1247–1254. Am J Hypertes.
2018; 31: 247-1254.
151. Danaei G SGPCLJCMFMea. The global cardiovascular risk transition:
associations of four metabolic risk factors with national income, urbanization,
and Western diet in in1980 and 2008. Circulation. 2013; 27(14): 493-502.
152. Chopra I, Kamal KM, Candrilli SD, Kanyongo G. Association between obesity
and therapeutic goal attainment in patients with concomitant hypertension and
dyslipidemia. Postgrad Med. 2014; 126(1): 66-77.
153. Koh KH, Goh CC, Goh SC, Koh YL, Tan NC. Blood pressure goal attainment
in multi-ethnic Asian patients with hypertension and dyslipidaemia in primary
care. Singapore Med J. 2020; 61(9): 460-475.
154. Choi HY, Im Jung Oh JA, Lim J, Kim YS, Jeon TH, et al. Factors affecting
adherence to antihypertensive medication. Korea J Fam Med. 2018; 39(6): 325332.
155. Chou CP, Chen CY, Huang KS, Lin SC, Huang CF, Koo M. Factors associated
with nonadherence to antihypertensive medication among middle-aged adults
with hypertension: findings from the Taiwan National Health Interview Survey.
J Int Med Res. 2020; 48(8): 1-10.

103
156. Bandi P, Goldmann E, Parikh NS, Farsi P, Boden-Albala B. Age-related
differences in antihypertensive medication adherence in Hispanics: a crosssectional community-based survey in New York city, 2011–2012. Prev Chronic
Dis. 2017; 14: E57. Doi: 10.5888/pcd14.160512.
157. Mahmood S, Jalal Z, Hadi MA, Orooj H, Shah KU. Non-Adherence to
prescribed antihypertensives in primary, secondary and tertiary healthcare
settings in Islamabad, Pakistan: a cross-sectional study. Patient Pref Adher.
2020; 14: 73-85.
158. Alkhamis AM, Alsalman AJ, Al Khamis M, Alkhamis A, Alotaibi NM.
Prevalence of nonadherence to antihypertensive medications among adults
attending primary healthcare clinics in Al-Hasa region: a cross-sectional study.
Dr. Sulaiman Al Habib Med J. 2019; 1(1): 36-43.
159. David R, Singh S, Isaac R.. A study of treatment adherence and control status of
diagnosed hypertensive patients in a rural community, Ludhiana. Int J Res
Health Sci. 2015; 3: 247-51.
160. Khayyat SM, Mohamed MM, Khayyat SM, Alhazmi RS, Korani MF, Allugmani
EB, et al. Association between medication adherence and quality of life of
patients with diabetes and hypertension attending primary care: a cross-sectional
survey. Qual Life Res. 2019; 28(4): 1053-61.
161. Euser AM, Zoccali C, Jager KJ, Dekker FW.. Cohort studies: prospective versus
retrospective. Nephron Clin Pract. 2009; 113(3): 214-7.
162. Vandenbroucke JP. Prospective or retrospective: what’s in a name? BMJ. 1991;
302: 249-250.
163. Carlson MD, Morrison RS.. Study design, precision, and validity in
observational studies. J Pallative Med. 2009; 12(1): 77-82.
164. Mulargia F. Retrospective selection bias (or the benefit of hindsight). Geophysic
J Int. 2001; 146(2): 489-96.
165. Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing,
and managing drug adherence in resistant hypertension. Hypertension. 2013; 62:
218-225.
166. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor
adherence: optimal cut-point for adherence measures using administrative
claims data. Curr Med Res Opin. 2009; 25: 2303-10.
167. Selby JV, Lee J, Swain BE, Tavel HM, Ho PM, Margolis KL, et al. Trends in
time to confirmation and recognition of new-onset hypertension, 2002-2006.
Hypertension. 2010; 56: 605-11.
168. Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV.. Description of
antihypertensive use in patients with resistant hypertension prescribed four or
more agents. Hypertension. 2011; 58: 1008-13.

104
169. Cardoso C, Salles GC, Salles GF.. Prognostic importance of on-treatment clinic
and ambulatory blood pressures in resistant hypertension: a cohort study..
Hypertension. 2020; 75: 1184-1194.

105
List of Publications
1. Bhagavathula AS, Shah SM, Aburawi EH. Medication adherence and treatmentresistant hypertension in newly treated hypertensive patients in the United Arab
Emirates. Journal of Clinical Medicine 2021; 10: 5036. Doi:
10.3390/jcm10215036. PMID: 34768553 Link: https://www.mdpi.com/20770383/10/21/5036/pdf
2. Bhagavathula AS, Shah SM, Aburawi EH. Prevalence, awareness, treatment, and
control of hypertension in the UAE: A systematic review and meta-analysis.
International Journal of Environmental Research and Public Health 2021; 18(23):
12693. Doi: PMID: 34886421 Link: https://www.mdpi.com/16604601/18/23/12693/pdf
3. Bhagavathula AS, Shah SM, Suliman A, Oulhaj A, Aburawi EH. Hypertension
control and guidelines‐recommended target blood pressure goal achievement at
an early stage of hypertension in the UAE. Journal of Clinical Medicine 2022;
11(1): 47. Doi: 10.3390/jcm11010047. PMID: 35011789 Link:
https://www.mdpi.com/2077-0383/11/1/47/pdf

106
Appendix
Appendix A: List of hospitals and data collection
Hospital

Number

Percent

Location

Settings

AA Al Ain Hospital

347

6.5

Urban

Tertiary

AA Behavioral Science

5

.1

Urban

Secondary

AH Bahia HC

133

2.5

Rural

Primary

AH Bani Yas HC

264

5.0

Rural

Primary

AH Bateen HC

229

4.3

Urban

Primary

AH Falah HC

46

.9

Rural

Primary

AH Faqah HC

12

.2

Rural

Primary

AH Hayar Health Center

29

.5

Rural

Primary

AH Hili Health Center

175

3.3

Urban

Primary

AH Jahli HC

189

3.6

Urban

Primary

AH Khalifa City A HC

150

2.8

Rural

Primary

AH Khatem Health Center

15

.3

Rural

Primary

AH Khazna Health Center

11

.2

Rural

Primary

AH Madinat Mohamed Bin Zayed
73
HC

1.4

Rural

Primary

AH Maqam Health Center

105

2.0

Rural

Primary

AH Maqtaa HC

59

1.1

Rural

Primary

AH Mezyad Health Center

198

3.7

Rural

Primary

AH Mushrif Children's Specialty
27
Center

.5

Urban

Primary

AH Muwaeji HC

74

1.4

Urban

Primary

AH Nahda HC

57

1.1

Rural

Primary

AH Naima HC

84

1.6

Urban

Primary

AH Niyadat Health Center

51

1.0

Urban

Primary

AH Oud Al Touba HC

302

5.7

Rural

Primary
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Percent

Location

Settings

AH Quaa Health Center

86

1.6

Urban

Primary

AH Remah Health Center

19

.4

Rural

Primary

AH Rowdha HC

52

1.0

Urban

Primary

AH Samha HC

43

.8

Rural

Primary

AH Shamkha HC

67

1.3

Rural

Primary

AH Shwaib Health Center

14

.3

Rural

Primary

AH Sweihan Health Center

16

.3

Rural

Primary

AH Towayya HC

101

1.9

Urban

Primary

AH Yahar Health Center

116

2.2

Rural

Primary

AH Zafrana HC

160

3.0

Urban

Primary

AH Zhaker Health Center

35

.7

Rural

Primary

GH Al Dhafra FMC

78

1.5

Rural

Primary

GH DL Delma Hospital

31

.6

Rural

Secondary

GH GY Gayathy Hospital

47

.9

Rural

Secondary

GH LW Liwa Hospital

29

.5

Rural

Secondary

GH MI Mirfa Hospital

45

.8

Rural

Secondary

GH MZ Madinat Zayed Hospital

74

1.4

Urban

Secondary

GH SA Silla Hospital

44

.8

Rural

Secondary

MQ Al Mafraq

418

7.9

Rural

Secondary

RH Al Rahba

102

1.9

Rural

Secondary

SK Diabetic Center

82

1.5

Urban

Primary

SK Sheikh Khalifa Medical City

284

5.4

Urban

Tertiary

TW Tawam Hospital

678

12.8

Urban

Tertiary

TWVIP

15

.3

Urban

Tertiary

TWWG Al Wagan Hospital

37

.7

Rural

Primary

Total

5308

100.0
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